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Preserving genome integrity is vital for protection against the development and 
progression of cancer. The SMC5/6 complex is an evolutionarily conserved protein 
complex thought to be involved in this process, specifically its SUMO ligase NSMCE2 
subunit. Prior to this thesis, CRISPR-Cas-9 mutant NSMCE2 cell lines were produced; 
NSMCE2 knockout, NSMCE2 knockout with wildtype NSMCE2 re-expression and 
NSMCE2 knockout cells with ligase-dead NSMCE2 expression. The purpose of this 
research was to characterize these cell lines with the aim of suggesting possible roles 
for NSMCE2. Both the NSMCE2 knockout and NSMCE2 ligase-dead cell lines 
demonstrated proliferation defects and slowed S phase progression by FACS 
analysis, with the defect exacerbated in the ligase-dead cells. The remainder of this 
project investigated the cause of these defects, determining that it is not due to the 
activation of the replication checkpoint, although the ligase-dead cell lines did 
activate the S phase DNA damage checkpoint. Based on what is already known about 
NSMCE2 function, it is suggested that the most likely cause of the proliferation 
defects is un-sensed, unresolved replication stress characteristics. Whilst other 
proteins may compensate for the total loss of NSMCE2, the ligase-dead cell line is 
expected to be the result of a dominant-negative mutation, which may explain the 
more pronounced S phase defect. The NSMCE2 ligase-dead cell lines also 
demonstrate a >4N DNA content, so it is speculated that unresolved replication 
stress characteristics may also cause segregation difficulties in this cell line. 
However, immunofluorescence and decatenation inhibitor treatment has shown 
that NSMCE2 may instead or also be involved in activating the decatenation 
checkpoint to allow for efficient segregation. A bioSUMO method for isolation of 
specific SUMOylation targets has also been developed with the aim to analyse 
specific NSMCE2 modifications within the future.  
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Chapter 1: Introduction 
 
1.1 Overview of Cancer  
 
 
Cancer is a collection of over 200 different life-changing diseases, affecting different 
tissues and cell types, all characterized by dysregulated cell growth and division, and 
usually, their ability to spread around the body. Most people within the UK will be 
affected in some way throughout their lives, with 1 in every 2 people receiving a cancer 
diagnosis (Cancer Research UK, 2014). For this reason, it is important that every effort 
is made to learn more about cancer formation and progression in order to support the 
development of new methods for prevention and treatment. 
 
Cancer cells all share a variety of characteristics which inherently define them as 
cancerous. Originally, six hallmarks of cancer were described; self-sufficiency in 
growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, 
limitless replicative potential, sustained angiogenesis and evading apoptosis (See Fig. 
1A) (Hanahan and Weinberg, 2000). More recently this list has been expanded to 
include two further emerging hallmarks which are involved in the pathogenesis of 
cancer (see Fig.1B). These are: deregulating cellular energetics, by which cancer cells 
reprogram their glucose metabolism to rely on aerobic glycolysis; and avoiding 
immune destruction, by which solid tumours have evolved to avoid cell death by 
becoming undetectable to all arms of the immune system. As well as emerging 
hallmarks, the list has also been expanded to include two enabling characteristics; 
genome instability and mutation, which drives genotypic changes that underpin 
phenotypic alterations in cell behavior; and tumour promoting inflammation, that 
provides the perfect microenvironment for cancer development through the supply of 




Figure 1 – A -The original six hallmarks of cancer. Cells acquire these capabilities to allow the  formation of  
malignant tumours. Figure taken from (Hanahan and Weinberg, 2000). B- The further four hallmarks of cancer; two 
emerging hallmarks involved in the pathogenesis of cancer, and two enabling characteristics which allow and 
encourage the development of the other hallmarks. Figure taken from (Hanahan and Weinberg, 2011). 
 
One of the key characteristics of a malignant tumour is its ability to proliferate with 
little to no control. This is highlighted by the fact that three of the six original cancer 
hallmarks describe the ways in which cells achieve this. During this dysregulated 
proliferation, tumour cells often experience high levels of replication stress (RS) 
(Gaillard et al., 2015). Therefore, cancer cells must be able to tolerate this RS in order 
to continue growing and dividing. Due to this reliance on RS tolerance mechanisms for 
cancer cell survival, there is significant interest in targeting these activities as a 
potential treatment strategy. For this reason, a key aim of this project is to characterize 
a poorly understood aspect of the RS response, with the goal of identifying new 
possibilities for therapeutic intervention.  
 
1.2 Genome instability 
 
Genome instability (GI), defined as an increased chance of genetic changes during cell 
growth and division, is a key feature of nearly all cancers. When cells are genetically 
unstable, they are more likely to acquire mutations which drive the development of 
additional cancer hallmarks, giving cancer cells a growth advantage and driving cancer 
progression (Yao and Dai, 2014).  
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There are two key hypotheses which associate GI with cancer formation; the mutator 
hypothesis and the oncogene-induced DNA replication stress model (OIRS) (see Fig. 2). 
The mutator hypothesis states that GI is an initiating feature of precancerous lesions, 
that causes an increase in spontaneous mutations, driving the development of the 
other hallmarks of cancer (Loeb, 1991). There is substantial evidence in support of this 
model in the case of hereditary cancers, where an inherited mutation, in a DNA repair 
gene for example, causes the initial genome instability allowing more mutations, and 
so, further cancer characteristics to arise (Loeb, 2016). Good examples of this include 
inherited mutations in nucleotide excision repair (NER) genes found in patients with 
Xeroderma pigmentosum (Cleaver, 1968), a genetic disease causing dyspigmentation 
of the skin and a predisposition to skin cancer. These patients develop skin cancer at 
much younger ages than the general population due to their mutated NER genes, 
which cause increased sensitivity to UV light, allowing further mutations to arise 
(Lambert and Lambert Muriel, 2014). The mutator hypothesis is also supported in the 
development of hereditary non-polyposis colorectal cancer, where affected patients 
have an inherited mutation in a single copy of a mismatch repair (MMR) gene. Somatic 
inactivation of the other MMR gene copy results in genetic instability, encouraging the 
development of colorectal (and other forms of) cancer (Peltomäki, 2001). Similarly, 
colorectal cancer can also be developed as a consequence of mutations in the proof 
reading catalytic subunits of DNA polymerases ɛ and δ, which also leads to the genome 
instability (Palles et al., 2012).  
 
By contrast, the oncogene-induced DNA replication stress model claims that, in most 
cancer cases, it is a sporadic mutation within an oncogene or tumour suppressor which 
initiates and drives the cancer formation through increased cell proliferation. This 
uncontrolled and increased proliferation causes increased RS which in turn leads to 
increased GI (Yao and Dai, 2014). In precancerous lesions, this increased RS and 
associated damage triggers the DNA damage response (DDR), activating p53 and 
causing cell cycle arrest, senescence or apoptosis. p53 acts as a tumourigenesis barrier 
preventing cancer development. However, ongoing RS and GI provides a continual 
pressure for p53 mutation, which would lead to the evasion of cell death (see Fig. 2) 
and impair the ability of the cell to repair damage. This explains why p53 mutations 
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are so common in cancer cells, as a mutation allows cells to avoid cell death following 
RS and GI, and so continue proliferating and generating further cancer hallmarks 
(Halazonetis et al., 2008).  
 
 
Figure 2 - Diagrammatic representation of the two main hypotheses describing how genome instability is involved 
in the initiation of cancer formation. Figure adapted  from (Negrini et al., 2010) by Dr Elaine Taylor 
 
1.3 The DNA damage response pathway  
 
The ability to deal with DNA damage effectively is vital for avoiding the harmful effects 
of RS and GI which drive carcinogenesis (Pause et al., 2003). DNA is constantly subject 
to damage, not only as a consequence of RS but also from free radical species, which 
are produced as a by-product of normal metabolic processes within the cell (Valko et 
al., 2006) as well as from exposure to various exogenous sources of damage such as 
ultraviolet light (which causes damage both directly and by the production of 
genetically damaging reactive oxygen species) (Schuch et al., 2017), ionizing radiation 
(Ward, 1988) and chemical carcinogens (Reviewed in: (Jackson and Bartek, 2009) 
 
The human body has evolved a complex network of pathways which it uses to deal 
with the various forms of DNA damage and alterations which result from these 
different damaging processes. In essence, the DNA damage response (DDR) is initiated 
by sensory molecules that each detect different types of DNA lesion and, through the 
action of specific transducer molecules, signal the presence of this DNA damage to a 
range of effector molecules (Fig. 3). These effectors trigger a number of cellular 
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responses to limit the consequences of this DNA damage. These responses include 
repair, cell cycle arrest, senescence or apoptosis (This pathway is reviewed in (Harper 




Figure 3 -The classical DNA damage response signalling pathway involving the 3 key molecules, sensors, transducers 
and effectors. Sensors sense the different forms of DNA damage within the cell before passing the information to 
transducers which can recruit many different effectors. The effectors can then carry out the response necessary to 
combat the damage formed (Reviewed in (Harper and Elledge, 2007).  
 
Like many other pathways within the cell, the DDR is controlled by phosphorylation. 
Two key molecules which act early in these signaling pathways, as sensors, are the 
phosphatidyl-inositol 3-OH kinase-like kinases, ATM (Ataxia telangiectasia mutated) 
and ATR (ATM and Rad Related) (Savitsky et al., 1995; Bentley et al., 1996). These 
kinases must be closely controlled in order to prevent dysregulated activation which 
would cause untimely cell cycle effects. For this reason, both ATM and ATR need 
specific co-factors for their recruitment and activation at sites of damage. For ATM this 
is the MRN complex, made up of MRE11, RAD50 and NBS1, whereas ATR requires 
ATRIP (Falck et al., 2005). Although there is some overlap between the roles of ATM 
and ATR in the DDR, ATR is predominantly activated by ssDNA, coated with Replication 
Protein A (RPA), that is generated by many different types of DNA damage, especially 
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during DNA replication, whilst ATM is largely activated by the presence of double 
strand breaks (DSBs) (Zou and Elledge, 2003; Shiloh, 2003).  Another key protein kinase 
involved in the early stages of the DNA damage response is the DNA-dependent 
Protein Kinase (DNA-PK). This kinase requires the co-factor Ku to become activated 
following DSBs (Dvir et al., 1992) (Gottlieb and Jackson, 1993). The recruitment and 
activation of these three important kinases is illustrated in Fig. 4.  
 
 
Figure 4 – Diagrammatic model of the recruitment and activation of the three key kinases in the early DNA damage 
response; ATR, ATM and DNA-dependent protein kinase (DNA-PK) Figure taken from (Blackford and Jackson, 2017).  
Following the activation of these early acting kinases of the DDR, there are over 700 
phosphorylated transducer and effector proteins that can, in turn, be activated 
(Matsuoka et al., 2007), allowing this network to become very complex and give a wide 
range of specific responses. Two of these transducer/effector proteins, which are 
found to work in close partnership with ATM and ATR, are the secondary kinases Chk1 
and Chk2. ATM is normally seen to interact with Chk2, and ATR with Chk1, however 




The activation of either Chk1 and Chk2 are essential to achieve cell cycle arrest. They 
both activate checkpoints within the cell cycle, allowing the cell extra time to deal with 
any issues faced during replication or following DNA damage. Chk1 is identified as the 
main activator of the S-phase replication checkpoint, through phosphorylation and 
inactivation of replication proteins, when cells have encountered problems during 
DNA replication. This halts replication until the issues have been dealt with, such as by 
preventing late origins from firing so that resources can be directed to the replication 
forks which need it, and ensuring that the cells do not enter G2 or mitosis until 
replication has been completed (González Besteiro and Gottifredi, 2015). Chk2, unlike 
Chk1, activates the G1/S checkpoint as well as the G2/M checkpoint, by 
phosphorylation of different targets in response to double strand breaks. For example, 
Chk2 can activate the G1/S checkpoint by phosphorylating p53 and activate the G2/M 
checkpoint by phosphorylating CDC25c (Chehab et al., 2000) (Matsuoka et al., 1998).  
 
Following cell cycle arrest, if there is any damage to the DNA, DNA repair pathways are 
activated to restore genome integrity. There are several different types of repair 
pathway which can be undertaken in response to DNA damage signaling depending on 
the type of damage incurred, including; base excision repair (BER), nucleotide excision 
repair (NER), ICL repair, SSBR, and repair of DSBs by repair homologous recombination 
(HR) or non-homologous end joining (NHEJ) (reviewed in: (Giglia-Mari et al., 2011) and 
(Caldecott, 2008).   
 
Ultimately, if the genetic damage cannot be repaired or the repair machinery becomes 
overwhelmed by the quantity of DNA damage, cells undergo cell death by activating a 
pathway such as apoptosis. Following damage, p53 is signaled to activate the 
transcription of both anti-apoptotic/repair genes (see Fig. 5) as well as pro-apoptotic 
genes. As the repair machinery cannot deal with the damage any longer, p53 allows 
for more pro-apoptotic gene transcription than repair gene and so causes the 





Figure 5 – The downstream signalling of DNA Damage to p53. p53 induces the transcription of both pro-apoptotic 
and DNA repair genes. Once the repair machinery becomes overwhelmed, the balance is shifted towards pro-
apoptotic protein production causing cell death to occur. Figure taken from (Roos and Kaina, 2013).  
1.4 Eukaryotic DNA replication 
 
When cells divide, they must accurately copy millions of individual base pairs. This is a 
very complex process and as such, has the possibility to become faulty and 
malfunction. To prevent this, cells have developed an intricate mechanism to tightly 
coordinate DNA replication, to minimize errors and avoid genome instability.  
 
In eukaryotes, replication of the entire genome occurs exactly once during S phase in 
each cell cycle in each cell. To ensure that replication of large eukaryotic genomes 
occurs quickly and efficiently, DNA replication occurs in parallel at many sites along 
the DNA, with replication forks proceeding in a bi-direction manner, copying the DNA 
until they reach another fork. The locations on eukaryotic DNA where replication 
begins are called origins. Activation of replication origins is tightly controlled and 
occurs as a two-step process, origin licensing and replication initiation. During G1, 
origin licensing takes place as the pre-replication complex is assembled at the origin. 
The pre-RC is made up of the Origin recognition complex (ORC), Cdc6, Cdt1 and the 
MCM2-7 replicative helicase (See Fig. 6). At this point, the pre-RC is in an inactive state 
and DNA replication will not begin unless it becomes activated through the initiation 
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step (Reviewed in: (Tanaka and Araki, 2010; Bell and Dutta, 2002)). Many more origins 
are licensed for replication than those that actually fire in S phase. The ones which do 
not fire are named dormant origin sites and these origins are reserved in case there 
are problems in S-phase and replication can then begin from a different site (Blow and 
Dutta, 2005).  
 
 
Figure 6 – The inactive pre-replication complex as found on eukaryotic dsDNA origins, made up of Mcm2-7, Origin 
recognition complex, cdc6 and cdt1.  Figure taken from (Duncker et al., 2009). 
Activation of the pre-RC to form the pre-IC begins in a cell cycle dependent manner 
which  
ensures the binding of a growing list of proteins, including Cdc45, GINS, Sld3, Sld2 and 
Dpb11, to the replication origins. The pre-IC can then be activated, forming an active 
replication complex, following helicase activation and the recruitment of DNA 
polymerases, allowing the replication forks to begin moving, bi-directionally, away 
from the origins, with MCM2-7 slightly ahead to open the dsDNA (see Fig. 7A) (Remus 
and Diffley, 2009; Méchali, 2010; Fragkos et al., 2015). Once the replication forks have 
moved away from their origins, they continue replicating the genome until they reach 
another replication fork. This occurs until the entire genome has been replicated (see 



















Figure 7 -A) Diagrammatic representation of two replication forks moving of bi-directionally on eukaryotic DNA at 
one replication origin. B) The overall process of eukaryotic DNA replication through the cell cycle, from replication 
origin licensing during G1 to firing and replication of the whole genome during S phase. Figure taken from (Méchali, 
2010) 
1.5 Replication Stress 
 
The complex process of DNA replication is susceptible to problems such as the slowing, 
stalling or even collapse of replication forks, termed replication stress (Zeman and 
Cimprich, 2014). There are many replication challenges which cause RS to arise during 
a 
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normal replication. These include physical blocks to the replication fork, lack of 
replication resources, collisions between the replication fork and transcriptional 
machinery, and dysregulated origin use (Mazouzi et al., 2014). Many of these 
impediments can be seen in Fig. 8.  
 
Figure 8 – Overview of some of the barriers faced by the replication forks during DNA replication which can cause 
replication stress. Figure taken from (Lambert and Carr, 2013).  
 
A physical obstacle within the genome can be extremely detrimental for replication. 
There are many different types of physical blocks to the progress of a replication fork, 
a key one being DNA lesions resulting from exogenous or endogenous damage 
(Lambert and Carr, 2013). Another form of physical obstacle faced by the replication 
machinery is protein-bound DNA. The helicases found in the replication complex 
struggle to unwind the dsDNA when it is protein-bound, causing the stalling and 
possible dissociation of the replication complex (Brüning et al., 2014). Secondary 
structures, commonly found within DNA, are also difficult for the replication 
machinery to pass through. For this reason, common fragile sites (due to their high 
A/T content), trinucleotide repeats and GC-rich DNA are problematic due to their 
tendency to form structures such as hairpins and G-quadraplexes (Mazouzi et al., 
2014; Zeman and Cimprich, 2014).  
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Similarly, RS can also be caused by a lack of replication resources such as nucleotides 
or components of the replication machinery. If this occurs, large exposed lengths of 
ssDNA will occur as the cells run out of the raw materials needed to continue 
replicating. The importance of this replication hindrance has been shown through the 
ability to rescue RS by exogenously supplying nucleosides (Poli et al., 2012; Bester et 
al., 2011).  
 
Conflicts between replication and other DNA associated processes can also lead to RS. 
For example, both the replication machinery and the transcription machinery are 
competing for the same dsDNA template, both unwinding the DNA, and carrying out 
their individual roles. Although coordinated closely, they are likely to come into 
contact with each other on occasions leading to replication fork stalling. It is thought 
that the stalling could occur due to head on collisions between the machinery but it 
has been shown that even before the two collide, there is an increase in RS and fork 
stalling due to their topological effects, such as the positive supercoiling, that they 
both create (Bermejo et al., 2012). Collisions are particularly likely when transcribing 
long genes in human cells as transcription can lead into a second cell cycle, where 
replication has begun again. When the machinery collides and replication is halted, R-
loops, interactions between DNA and RNA, can form (as shown in Fig. 8). This can lead 
to severe genetic damage such as DSB’s as RNA displaces the template DNA strand, 
causing further RS and obstruction to the replication machinery (Helmrich et al., 2011) 
 
Unregulated origin usage can also influence RS. To prevent re-replication, origins are 
usually unable to be licensed after the start of S-phase, even if a problem arises during 
replication. This means that there would be no replacement replication machinery if a 
fork were to collapse, and many sections of DNA would be left un-replicated. To avoid 
this situation, cells normally license more origins than they fire at the start of S phase, 
leaving many origins lying dormant unless they are required. However, this can lead 
to RS if not appropriately regulated, for example, if too many or too few origins are 
fired or if origins are able to re-fire (Alver et al., 2014). If, at the start of S phase, not 
enough origins are fired for replication, then isolated replication forks will arise. These 
forks would need to travel further, increasing the likelihood of stalling and possibly 
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collapsing. If not enough origins have been licensed either, this would be a genetic 
catastrophe as there would be fewer dormant origins to replace the stalled forks so 
the genome could not be entirely replicated. Further issues could arise following 
reduced origin firing as there would be an increased chance that the genome would 
only be part replicated before entering mitosis, even assuming no replication 
challenges occur. This would not only cause the loss of genetic material, but it would 
also mean that the sister chromatids will still be linked during cytokinesis so the DNA 
strands would break and not segregate equally (Hills and Diffley, 2014). If the opposite 
occurs and too many origins are fired, the replication machinery may be unable to 
continue replicating due to a shortage of replication substrates, such as nucleotides, 
as well as the increased likelihood of collisions between transcriptional and replication 
machinery, causing RS as described above (Beck et al., 2012; Jones et al., 2013). There 
is also the possibility that origins could re-fire. This dysregulated re-firing would lead 
to the detrimental replication consequences described if there were too many origins 
fired, as well as the possibility that the replication forks themselves could collide into 
each other as the forks would be found closer together (Taylor and Lindsay, 2015).  
 
Oncogene-induced RS 
By driving dysregulated cell proliferation, activation of oncogenes or inactivation of 
tumour suppressors can lead to RS by a variety of mechanisms. One key problem that 
arises from untimely and increased replication is a lack of nucleotides needed to keep 
up with this replication. This was demonstrated to be the case when the Cyclin E 
oncogene is activated, stimulating the Rb-E2F pathway which caused disturbed 
replication and RS. This RS phenotype could be reversed with the addition of 
exogenous nucleosides, establishing that it was the nucleosides which were the 
limiting factor and cause of the RS in this case (Bester et al., 2011). However, although 
this is one way by which oncogenes can cause RS, it is clear that this is not always the 
case. For example, Cyclin E overexpression can also cause RS by increasing origin firing. 
This can cause conflicts between the replication and transcription machinery as 
described above, leading to compromised fork progression (Jones et al., 2013). The 
MYC oncogene is one of the master regulators of the cell cycle, influencing the 
expression of many genes involved in proliferation such as cyclin dependent kinases 
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(CDKs). MYC overexpression is a common occurrence in many cancers and it has been 
shown to increase RS by increasing origin licensing density as well as altering the origin 
firing pattern such as by influencing replication timing and increasing the number of 
early-replicating origins (Srinivasan et al., 2013). Overexpression of the oncogenes RAS 
and MOS also produces RS by upregulating the expression of CDC6 and so causing an 
increase in active origins and replication forks, thereby resulting in the RS phenotypes 
described above (Di Micco et al., 2006; Bartkova et al., 2006). As well as resulting from 
oncogene activation, RS can also be a consequence of loss of the tumour suppressor 
gene p53. Where p53 is functional, even following over-expression of the replication 
initiation factors Cdt1 and cdc6, p53 can prevent re-replication from a single origin 
through the activation of p21. However, following p53 tumour suppressor 
inactivation, as found in many cancer cells, re-replication of the genome is permitted, 
and so RS occurs at a much higher rate (Vaziri et al., 2003).   
 
1.6 The replication stress response  
 
Replication fork stalling following RS causes the uncoupling of the MCM helicase from 
the DNA polymerase upon the replication fork. To continue replication, the replication 
complex therefore needs to reform and it does so upon the activation of the 
replication checkpoint (Mourón et al., 2013). The uncoupling of the replication 
machinery is a vital signal for the activation of this replication checkpoint as it causes 
the unwinding of dsDNA to ssDNA behind the helicase but ahead of the stalled 
replication machinery. This region of ssDNA becomes coated in Replication Protein A 
(RPA), stabilizing the ssDNA and serving as the site of localisation and activation of ATR 
along with its interacting partner ATRIP (Zou and Elledge, 2003). It is the junction of 
ssDNA with dsDNA at the fork stall that is the vital structure required for the binding 
and activation of ATR-ATRIP, as ATRIP interacts with RPA. As well as the recruitment 
of ATR/ATRIP to the stalled forks, for complete activation of the replication 
checkpoint, both the RAD17-RFC and Rad9-Rad1-Hus1 (9-1-1) complexes need to be 
recruited to the site, with the RAD17-RCF clamp loader complex acting as a loader for 
the 9-1-1 complex onto stalled fork site (Ellison and Stillman, 2003). The loaded 9-1-1 
complex is then vital for the activation of a further replication checkpoint protein, the 
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DNA topoisomerase II binding protein 1 (TOPBP1), which is initially recruited through 
the presence of ATRIP and the MRN complex (Duursma et al., 2013; Choi et al., 2010). 
It is currently thought that it is the N-terminus of TOPBP1 which stabilizes the entire 
checkpoint complex and stimulates the full kinase activity of ATR, allowing it to 
interact with its downstream effectors (Choi et al., 2010). The mechanism of ATR-
ATRIP activation can be seen in Fig. 9, demonstrating the interdependency each of the 
checkpoint activation proteins has upon each other.  
 
 
Figure 9 - The activation of ATR-ATRIP following replication stress. The activation of ATR requires all of the molecules 
shown in this diagram; Replication protein A (RPA, RAD17-RCF, The 9-1-1 complex, TOPBP1 and a possible unknown 
protein ‘X’.   Figure taken from (Flynn and Zou, 2011).  
As discussed earlier, the activation of the downstream kinase Chk1 by ATR is an 
important element of the replication checkpoint. As with most biological processes, it 
is not as simple as ATR phosphorylating Chk1 alone, there are other vital proteins 
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required for this activation to occur. In this case, it has been found that the mammalian 
proteins, Timeless and Tipin, promote the phosphorylation of Chk1 by ATR through 
interactions with RPA on ssDNA and by promoting Claspin (Mrc1) protein activation 
which then binds to Chk1 (Kemp et al., 2010). Recently, it has been demonstrated that 
the And-1 protein is also involved in promoting Chk1 activation (see Fig. 10). At the 
site of RS, there is an increase in And-1 which becomes phosphorylated by ATR, 
allowing And-1 to interact with Claspin (Mrc1). This association is required for Chk1 to 
bind to Claspin, and so be phosphorylated by ATR. These interactions allow for 
efficient activation of Chk1 and so give rise to all of the replication checkpoint effects 




Figure 10 - Activation of Chk1 by ATR through interactions with And-1 and Claspin. Figure taken from (Hao et al., 
2015) 
Upon phosphorylation of Chk1, the S phase replication checkpoint can then be 
effected in full through phosphorylation of proteins which produce cell cycle arrest, 
reduced origin firing, replication fork stabilization, removal of the source of RS, and 
replication fork restart.  
 
Importantly, to allow for cell cycle arrest and to inhibit origin firing, ATR/Chk1 quickly 
induces the degradation of Cdc25A, through phosphorylation, which causes the 
inhibition CDK2 which is required for entry into G2 (Sørensen et al., 2003). To ensure 
adequate time is given to allow recovery, ATR/Chk1 kinase activity also reduces the 
number of new active origins following RS through the inhibition of proteins involved 
in origin licensing, although some dormant origins near the site of RS are permitted to 
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fire to aid the DNA recovery (Ge and Blow, 2010). As well as allowing for cell cycle 
arrest, ATR must also act quickly to stabilize and promote recovery of the stalled fork, 
to reduce GI and ensure the fork does not collapse before recovery takes place. This is 
achieved by ATR-dependent phosphorylation of various recovery proteins including 
WRN, SMARCAL1 as well as the AND-1 protein discussed above, which prevent 
aberrant fork structures from arising (Ammazzalorso et al., 2010; Couch et al., 2013; 
Hao et al., 2015; Syljuåsen et al., 2005).  
 
As the cell cycle becomes arrested and stalled forks become stabilized, fork recovery, 
removal of the RS source and repair of the replication stress feature can then begin. 
One of the key causes of RS can be the lack of nucleosides. The kinase activity of Chk1 
activates E2F6 which leads to the activation of genes involved in nucleoside synthesis, 
removing the stress and so allowing replication to continue (Bertoli et al., 2013). RS is 
also often caused by physical blocks to the genome and so ATR/Chk1 activation 
provides the ability to activate the DNA damage response, to remove these blockages 
and restart the replication fork. These processes mainly occur through HR-dependent 
mechanisms which involve the DNA becoming reprimed, degraded or rearranged (fork 
reversal) in order to form a functioning replication fork once more. These techniques, 
shown in Fig. 11, are different depending on whether the replication challenge is found 
on the leading or lagging strand. Many of the HR mechanisms used to reform the 
replication fork on the leading strand (Figure 11A) do not actually repair any damage 
but simply tolerate and move around it. This is the case when the fork is reprimed and 
repaired (Figure 11A - 2b, 3c, 4c and 4b) and when fork reversal is carried out causing 
chicken foot RS intermediates (Figure 11A - 2b, 3d, 4d and 5d) (Li and Heyer, 2008). 
The involvement of ATR/Chk1 in the process of fork restart is vital, as a critical HR 
protein, Rad51, is directly activated by Chk1, whilst BRCA1 is activated by ATR 
(Sørensen et al., 2005; Tibbetts et al., 2000). Low-fidelity translesion synthesis 
polymerases such as POLH, POLI, and REV1, can also be used to tolerate the challenge 
rather than repair it, by moving through the lesion (Figure 11A - 3b) and replicating 
the DNA despite its complications (Sale et al., 2012). The most effective pathway 
allows for the repair of the initial replication block (Figure 11A - 1, 2a, 3a, 4a, 5a) 
through the cleavage of the stalled fork to form a double strand break. This break can 
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then also be repaired through HR (Li and Heyer, 2008), again stimulated through ATR 
and Chk1.   
 
The pathways are marginally different when the blockage is found on the lagging-
strand (Figure 11B), with all pathways beginning with re-initiation of synthesis 
downstream leaving a gap around the blockage (Figure 11B - 1) and ending with 
tolerance of the replication challenge (Figure 11B- 4). These mechanisms involve the 
use of a paranemic joint (Figure 11B - 3a), D-loop (Figure 11B- 2b and 3b) or translesion 
synthesis polymerases (Figure 11 - 2c) (Li and Heyer, 2008). 
 
 
Figure 11 - Mechanisms of re-starting stalled or broken replication forks using homologous recombination 
pathways. This diagram shows the different pathways undertaken depending if the lesion is found within the leading 
or lagging strand during replication. Most of the pathways do not repair the damage found within the replication 
fork but simply tolerate it using homologous recombination mechanisms, through either repriming and repairing, 
fork reversal or the action of translesion synthesis polymerases (11A - 2b, 3c, 3d, 4c, 4d, 5c and 5d, 11B), however 
the replication blockage can be repaired through fork cleavage and homologous repair (11A 2a, 3a, 4a and 5a). 
Figure taken from (Li and Heyer, 2008).  
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As well as the fork reversal and re-priming mechanisms described above, an 
alternative mechanism using nucleases to degrade the replication challenge has a role 
in restarting stalled forks after genotoxic stress. DNA2 nuclease has been shown to 
degrade the reversed replication fork DNA and restart the replication machinery 
meaning no intermediates are formed (Thangavel et al., 2015).  
 
Once the fork has been reformed through any of the mechanisms described, DNA 
replication can continue until the entire genome has been replicated.  
 
If the stalled forks cannot be restarted, the replication fork will eventually collapse due 
to their unstable nature. If forks do collapse then double strand breaks frequently 
occur which can cause serious damage to the genetic material and possible cell death 
(Marians, 2000).  
 
The three-stage checkpoint activated HR pathway is often used to repair these double 
strand breaks, as well as to remove byproducts and intermediates of RS such as 
intrastrand crosslinks and cruciform structures. The general process of HR when 
repairing a double strand break is shown in Fig. 12. As this figure shows, the process 
of repairing double strand breaks through HR can occur through three different forms; 
synthesis dependent strand annealing (SDSA), Break induced repair (BIR) or double 
strand break repair (DSBR). The majority of these repair mechanisms cause large 
sections of loss of heterozygosity (LOH) as a full replication fork is formed, but some 
DSBR products do demonstrate crossover products after Holliday junction formation 
(Li and Heyer, 2008). DSBs which occur following fork collapse are mainly repaired 
through BIR as they only possess one free DNA end, losing genetic material through 
LOH. However, if two collapses occur close together, DSBR mechanisms can be used 









Figure 12 - Homologous recombination pathway following the occurrence of a double strand break formed following 
fork collapse. The pathway involves 3 key stages; presynapsis, synapsis and post synapsis, where the mechanism 
could take forms of homologous recombination; synthesis dependent strand annealing, break induced repair and 
double strand break repair. Figure taken from(Li and Heyer, 2008).   
1.7 SMC proteins and the SMC5/6 complex  
 
Structural maintenance of chromosomes (SMC) proteins are found in all forms of life 
from bacteria to humans. These essential proteins act as molecular DNA linkers, which 
organize the structure and function of chromosomes throughout the cell cycle, and 
are vital for the survival of many forms of life (Losada and Hirano, 2005).  
 
SMC proteins are large polypeptides of up to 1300 amino acids in length, which share 
a characteristic domain structure. This comprises two nucleotide binding domains, one 
found at each the N and C terminal domains, separated by two extensive coiled coil 
domains and a flexible hinge region at the centre (Hirano, 2006). Each SMC protein 
folds at the central hinge region such that the coiled region forms antiparallel dimers 
and the Walker A and Walker B ATP binding and hydrolysis motifs within the terminal 
domains are brought together to form the ATP binding ‘head’ domain. The individual 
SMC proteins then come together to form dimers, interacting through the hinge 
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regions, allowing the formation of the well known V-shape, shown in Fig. 13 (Melby et 
al., 1998). In prokaryotes, these complexes are homodimers but in eukaroyotes, six 
SMC proteins interact in specific heterodimer combinations, in association with other 
complex components, to undertake vital chromosome organizational roles. These are 
cohesin, containing SMC1 and SMC3, condensin, containing SMC2 and SMC4 and the 
SMC5/6 complex, based on a heterodimer of SMC5 and SMC6 (Hirano, 2006). Both 
cohesin and condensin have the classic architectural V- shape (see Fig. 14). The 
primary function of cohesin is well established as the cohesion protein that links sister 
chromatids, and is therefore important for chromosome segregation in mitosis. It is 
also crucial for efficient DNA repair and controlling gene expression throughout the 
cell cycle (Peters et al., 2008). Condensins, of which there are two in eukaryotes, play 
a role in the overall shaping of eukaryotic chromosomes, organising the structure in 
chromosome assembly as well as in segregation throughout the stages of mitosis 






Figure 13 – Diagrammatic representation of the basic structure of an SMC dimer. The two monomers interact at the 
hinge region forming the well-known ‘V shape’ with antiparallel regions (indicated by the arrows) leading to the 
nucleotide binding head regions. Figure taken from (Hirano, 2006).  
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Figure 14 - Diagrammatic representation of the structure of the SMC protein complexes, Cohesin and Condensin. 
Both have the classic SMC dimer V-shape with the two SMC proteins interacting at the hinge region, as well as non-
SMC subunits, such as the kleisin components, RAD21 in Cohesin and CAPD3 (H) in Condensin, which interact with 
the SMC proteins at the head domains to connect the two heads. Figure taken from (Yuen and Gerton, 2018) 
The remaining SMC complex, SMC5/6, has a much less well known role in chromosome 
organization but is thought to be involved in RS recovery and repair. The first 
component of the SMC5/6 complex to be identified was the product of the 
Schizosaccharomyces pombe (S. pombe) rad18 gene (Lehmann et al., 1995), later 
renamed smc6 as sequence analysis revealed the Rad18/Smc6 protein to be a new 
member of the SMC family. S. pombe Smc6 was subsequently shown to be part of a 
larger complex comprising its heterodimeric SMC partner, Spr18/SMC5 along with six 
non-SMC element proteins (Fousteri and Lehmann, 2000) (McDonald et al., 2003). Of 
these, Nse1-4 were initially identified and were found to be highly conserved between 
both budding and fission yeast. Upon their discovery, it was first indicated that the 
complex may play an important role in DNA repair through sensitivity of yeast in 
SMC5/6 mutants to DNA damaging agents (Fujioka et al., 2002) (McDonald et al., 2003) 
(Pebernard et al., 2004) (Hu et al., 2005). The two further non-SMC complex 
components were then identified, Nse5 and Nse6, which were found to be essential 
in S. pombe but non-essential in Saccharomyces cerevisiae (S. cerevisiae) (Pebernard 
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et al., 2006) (Duan et al., 2009). The structure of the SMC5/6 complex in both yeast 




Figure 15 -Diagrammatic representation of the architecture of the yeast strains of the SMC5/6 complex.  Figure 
taken from (Verver et al., 2016a) 
 
As shown in Fig. 15, the yeast SMC5/6 complexes also have the characteristic V-shape 
expected from an SMC protein dimer, with Nse4 in a highly-conserved location as it 
bridges the gap between the head domains. The C-terminal domain of Nse4 directly 
interacts with the head of SMC5, much like the kleisin components, RAD21 and CAPD3 
of Cohesin and Condensin (Palecek et al., 2006). Nse4 also directly binds to both Nse1 
and Nse3 (Palecek et al., 2006; Pebernard et al., 2008). Nse3 contains a MAGE 
(melanoma-associated antigen gene) domain and it has been shown to enhance the 
activity of its binding partner Nse1, a ubiquitin ligase protein (Pebernard et al., 2004; 
Doyle et al., 2010). As well as the Nse1 ubiquitin ligase, the SMC5/6 complex has 
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another ligase function in Nse2, an E3 SUMO ligase. These ligase proteins are not 
found in other SMC complexes but are conserved in the SMC5/6 complex in all known 
organisms (McDonald et al., 2003). The positioning of NSMCE2 upon the coiled section 
of SMC5 is markedly different compared to the other non-SMC components of the 
other SMC complexes. The Nse5 and Nse6 components share little sequence 
homology between the two yeast species and were also found to be associated with 
different positions within the complex in the two yeasts, as shown in Fig. 15 
(Pebernard et al., 2006) (Duan et al., 2009).   
Following the discovery of each of the SMC5/6 components in the two yeast strains, 
human orthologs of each SMC5/6 complex component were also identified. The SMC6 
and SMC5 genes and their protein products were identified relatively quickly (Taylor 
et al., 2001), followed by NSMCE1-4, the orthologs of Nse1-4 (Harvey et al., 2004; Potts 
and Yu, 2005; Taylor et al., 2008). Recently, the Nse5 and Nse6 equivalents, SLF1 and 
SLF2, were also discovered in human cells. These proteins have little homology with 
either of the yeast Nse5 and Nse6 proteins and they are not part of the core complex 
(Räschle et al., 2015). However, the ligase activities of both the NSMCE1 and NSMCE2 
components have been confirmed in the human SMC5/6 complex, further indicating 
that they are evolutionarily and functionally important (Potts and Yu, 2005; Doyle et 
al., 2010). The likely structure of the SMC5/6 complex including its non-SMC proteins 




Figure 16 -Diagrammatic representation of the architecture of the SMC5/6 complex in mammals.  Figure taken from 
(Verver et al., 2016a) 
1.8 Functional roles of the SMC5/6 complex 
 
The SMC5/6 complex has been associated with maintaining genome stability since the 
very beginning of its discovery. The initial functional work surrounding the complex 
was undertaken in yeast (S. pombe and S. cerevisiae) before being extended to 
mammalian cells and, more recently, to human patients.  
 
Since the first discovery of Smc6 through complementation of the DNA damage 
sensitivity of a yeast mutant, studies of the SMC5/6 complex have tended to focus on 
its role in DNA repair (Lehmann et al., 1995). Initially, yeast mutants of SMC5/6 
complex components were shown to be sensitive to a wide range of DNA damaging 
agents (Andrews et al., 2005; Verkade et al., 1999; Fujioka et al., 2002; McDonald et 
al., 2003; Pebernard et al., 2004; Hu et al., 2005) with genetic analysis in S. pombe 
suggesting a role in HR-dependent double strand break repair, along with RAD51 
(McDonald et al., 2003; Harvey et al., 2004; Pebernard et al., 2004). Following this, 
studies in S. cerevisiae demonstrated that Myc-tagged SMC6 associated 5-7 fold more 
with the DNA regions flanking DSBs than when no breaks were present, further 
 35 
supporting that the complex was involved in DSB repair (De Piccoli et al., 2006). Again, 
genetic analysis indicated that this involvement related to HR-dependent repair of 
dsbreaks (De Piccoli et al., 2006). This data was supported in NSMCE2 siRNA 
knockdown studies in human cells, where their ability to carry out HR was decreased 
but there was no effect upon NHEJ (Potts et al., 2006). Consistent with these results, 
analysis of mutant SMC5/6 complex strains of A. thaliana and DT40 chicken cells each 
confirmed that the SMC5/6 complex facilitates HR between sister chromatids 
(Watanabe et al., 2009; Stephan et al., 2011a).  
 
Further analysis in yeast has revealed that the SMC5/6 complex plays a vital role when 
cells are subject to RS. This was initially discovered in S. pombe where analysis of smc6 
mutants indicated that the complex was vital in the resolution of DNA intermediate 
structures formed following replication fork collapse (Ampatzidou et al., 2006). It was 
suggested that the SMC5/6 complex may have two roles in RS recovery, both an early 
and late stage function. It is thought that once the stalled replication forks are 
stabilized, the early function of the complex is to restart the replication fork through 
the loading of Rad52 and RPA onto the chromatin, maintaining an appropriate 
configuration. The late stage function involves the resolution of collapsed fork 
intermediates and fork resetting through HR before replication can restart (Irmisch et 
al., 2009). These two functions, early and late, can be seen in Fig. 17. The late stage 
function was supported by studies in S. cerevisiae Mms21/nse2 mutants, which 
demonstrated that the complex was involved with the resolution of recombination 
intermediates such as cruciform structures, often the result of collapsed replication 
forks, as part of the RS recovery (Branzei et al., 2006). Additionally, the early RS 
recovery function of the SMC5/6 initially found in S. pombe was later corroborated in 
S. cerevisiae (Bustard et al., 2012), where the complex was shown to be vital in 





Figure 17 - Diagrammatic representation of the two functions of the SMC5/6 complex in homologous recombination 
following replication stress. The early function requires the SMC5/6 complex to restart replication in a stalled fork 
by recruiting Replication Protein A and rad52. The late function of SMC5/6 is to move intermediate structures from 
collapsed replication forks in order to restart normal replication.  Figure adapted  from (Irmisch et al., 2009).  
 
Several studies have analysed the role the SMC5/6 complex plays in the replication 
and stable maintenance of ribosomal DNA (rDNA). It was shown in S. pombe and S. 
cerevisiae that the complex is enriched at the ribosomal gene array (Torres-Rosell et 
al., 2005; Ampatzidou et al., 2006), indicating that the SMC5/6 complex may have a 
specific role in this area of DNA. This was supported in S. cerevisiae where rDNA 
regions were associated with increased collapsed fork RS intermediates as well 
segregation defects in SMC5/6 mutants (Torres-Rosell et al., 2005). rDNA is replicated 
unidirectionally, which means that replication forks cannot converge to continue 
replication when one stalls. This means that stalled or collapsed forks must be 
recovered, in order to complete the replication. Because of this, it has been suggested 
that the effects seen within mutant SMC5/6 cells are just an exaggerated version of 
those seen in the rest of the genome as the RS recovery functions are even more 
important in rDNA regions. This is supported further as rDNA is made up of repeat 
units which are inherently susceptible to RS (Murray and Carr, 2008). Moreover, it has 
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recently been found in S. cerevisiae that the SMC5/6 complex plays a vital role in 
allowing replication through natural pausing sites as well as processing DNA structures 
formed during DNA damage tolerance pathways following RS. These features are 
frequently found, although not exclusively, in rDNA (Menolfi et al., 2015; Peng et al., 
2018). This study gives further support that the genome maintenance and repair role 
of SMC5/6 occurs genome wide but is more significant in rDNA due to its susceptibility 
to fork stalling and the reduced back-up capabilities.  
 
Extensive research supports a role for the SMC5/6 complex in HR, both within DNA 
damage repair and RS recovery, however some questions were also thrown up. In 
particular, yeast SMC5/6 components are encoded by essential genes, yet classical HR 
genes are not essential in yeast, suggesting a role for SMC5/6 beyond HR (Murray and 
Carr, 2008) This gave big clues that the function of the SMC5/6 complex did not solely 
like in HR, but it must also have roles outside of this as well.  
 
There have been various studies undertaken which indicate that one of the key 
functions of the SMC5/6 complex lies within maintaining chromosome architecture. 
The initial evidence to suggest this comes from budding yeast where the association 
of the SMC5/6 complex to DNA is chromosome length dependent, i.e. the longer the 
chromosomes, the higher the interaction rates (Betts Lindroos et al., 2006; Kegel et 
al., 2011). This suggested that the complex must be able to ‘sense’ the length of the 
chromosomes, possibly due to topological stress. Topological stress is the stress within 
dsDNA that occurs as the two strands separate in order to allow replication. The DNA 
ahead of the fork becomes supercoiled, and these supercoils need to be removed by 
topoisomerases in order to allow complete replication (Keszthelyi et al., 2016). If the 
SMC5/6 complex was to be involved with the removal of topological stress, then it may 
interact with topoisomerases. This was supported in S. pombe, where overexpression 
of Smc6 led to nuclear changes similar to those following the loss of topoisomerases I 
and II, and in S. cerevisiae where the SMC5/6 association with longer chromosomes 
was topoisomerase dependent (Harvey et al., 2004; Kegel et al., 2011). A study in S. 
cerevisiae later found that the SMC5/6 complex is loaded onto sites of topological 
stress by cohesin, demonstrating an interplay between these SMC complexes 
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(Jeppsson et al., 2014). This was supported in human cells where the SMC5/6 complex 
was shown to associate with chromatin throughout the cell cycle in the same pattern 
as cohesin. This study also found that the SMC5/6 complex may interact with 
condensins as well as TopoII directly in order to organize and coordinate chromosome 
architecture, indicating further interplay between the SMC complexes for 
chromosome maintenance (Gallego-Paez et al., 2014).  
 
It is thought that one of the main purposes for interactions between cohesin and the 
SMC5/6 complex is for ensuring accurate chromosome segregation. Studies in S. 
pombe demonstrated a failure to complete mitosis in some SMC5/6 mutants due to 
the inability of these cells to remove cohesin from the chromosome arms (Outwin et 
al., 2009). Early studies have often suggested a role in chromosome segregation for 
the SMC5/6 complex. Temperature sensitive smc6 S. pombe mutants demonstrated 
that without the complete complex, cells exhibit incomplete segregation of 
chromosomes, with the chromatids often found to be stretched along the division 
plane (Harvey et al., 2004; Sergeant et al., 2005). Moreover, a role for the SMC5/6 
complex in chromosome segregation was also indicated as it was demonstrated that 
the SMC5/6 complex is necessary for the segregation of repetitive regions of DNA 
(Torres-Rosell et al., 2005). However, there are two main types of connections found 
between sister chromatids which need to be resolved before segregation; cohesin 
protein connections as well as DNA mediated linkages. DNA mediated linkages can be 
further divided into catenations which are formed as sister chromatids pair up during 
normal replication, resolved by condensin and Topoisomerases, as well as other DNA 
mediated linkages such as unresolved RS characteristics and unfinished DNA 
replication. It was shown by Bermúdez-López et al., (2010) that in S. cerevisiae the 
main connection removed for segregation by the SMC5/6 complex was the DNA 
mediated linkages caused by unfinished replication structures, not the removal of 
cohesin as previously believed. This was also shown by Branzei et al., 2006, in mutant 
S. cerevisiae cells which expressed non-functional SMC5/6. Furthermore, mutant 
SMC5/6 cells were also shown to undergo catastrophic meiotic divisions as DNA 
linkages between the chromosomes remained as inappropriate meiotic segregation 
was attempted (Farmer et al., 2011). On the other hand, in SMC5 knockout mouse 
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embryonic stem cells, it has also been revealed that the loss of SMC5/6 causes reduced 
chromosome segregation possibly due to abnormal condensin localization, implicating 
the complex in removal of catenations (Pryzhkova and Jordan, 2016). A study within 
human cells has also shown that depletion of Smc5 and Smc6 caused segregation 
defects, possibly causally related to an abnormal distribution of condensins and 
topoisomerase II (Gallego-Paez et al., 2014). This indicates that the pathway is not as 
clear as first expected and the complex may aid segregation through several different 
pathways along with being cell type and/or species specific.  
 
In recent years, as well as cellular research to attempt to identify the function of the 
SMC5/6 complex, several patient studies have been undertaken. Four clinical patients 
have been identified carrying NSMCE3 mutations which resulted in early childhood 
death after development of pulmonary disease and viral pneumonia. As the NSMCE3 
subunit is an integral part of the SMC5/6 complex architecture, loss of NSMCE3 
destabilises the entire complex so the effects seen are thought to be the result of the 
loss of the entire complex, not solely NSMCE3. The patients presented with T and B 
cell immunodeficiency, indicating that the SMC5/6 complex plays a role in human 
lymphocyte development, as well as cells from these patients displaying defective HR 
repair, increased chromosome breakage, increased sensitivity to DNA damaging 
agents, increased numbers of micronuclei, and RS sensitivity at a molecular level (van 
der Crabben et al., 2016). These phenotypes support much of the previous research 
associating the SMC5/6 complex with HR repair and recovery from RS, indicating that 
the complex functions similarly in a whole organism as previously shown on a cellular 
level. Patients presenting with NSMCE2 mutations have also been investigated. These 
patients displayed primordial dwarfism, gonadal failure and insulin resistance as well 
as increased numbers of micronuclei and nucleoplasmic bridges at a molecular level. 
The cells from these patients demonstrated a clear reduction in RS recovery which the 
study indicated was due to loss of the NSMCE2 SUMO ligase function (Payne et al., 
2014). These findings were supported by an NSMCE2 study in mice where knockouts 
demonstrated an increase in cancer and aging as well as presenting with Blooms 
syndrome hallmarks such as difficulty segregating their DNA, increased recombination 
as well as micronuclei. The similarity between these characteristics and Blooms 
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syndrome further suggest that it is most likely resolving DNA mediated linkages which 
the SMC5/6 complex undertakes before chromosome segregation. However, many of 
these molecular features were surprisingly shown to be independent of the NSMCE2 
SUMO ligase function in mice, suggesting that the function of the NSMCE2 subunit 
may not be as simple as first anticipated (Jacome et al., 2015). 
 
It is clear from the literature that the SMC5/6 complex may play a wide range of roles 
in maintaining genome stability during DNA replication and segregation. It is possible 
that the complex may be acting as an all-round control unit for these processes, 
possibly through the NSMCE2 SUMO ligase subunit which could potentially interact 
with a wide range of substrates.  
 
1.9 Mechanism of SUMOylation 
 
SUMOylation is an essential post-translational protein modification in eukaryotic cells 
which can alter protein interactions and localization within cells. It has been linked to 
the development of diseases such as neurodegeneration (Droescher et al., 2013) and 
heart failure (Kho et al., 2011) and plays a role in a wide variety of biological processes. 
The mechanism of SUMOylation is a very similar concept to ubiquitination, involving 
the covalent attachment of SUMO (small ubiquitin-like modifier) molecules to lysine 
residues within target proteins via an enzyme cascade (Wilkinson and Henley, 2010).  
 
There are four paralogues of SUMO proteins found within mammals, SUMO-1-4. 
SUMO-1 was discovered first, having roles in DNA strand exchange, binding to 
RAD51/52 (Shen et al., 1996), as well as binding to the tumour suppressor PML protein 
(Boddy et al., 1996). The discovery of SUMO-2 protein closely followed (Mannen et al., 
1996) and the SUMO-2 and SUMO-3 human genes were then confirmed. Research 
showed that these genes shared 87% identity, whilst 47% identity was shared between 
SUMO-1 and SUMO-3 (Lapenta et al., 1997), verifying these proteins as the human 
SUMO gene family. Following this, a relatively unknown SUMO was also identified, 
SUMO-4. This SUMO molecule is intron-less and found mainly in the kidney (Bohren 
et al., 2004). It has been questioned whether SUMO-4 can in fact SUMOylate targets 
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due to an inhibitory proline residue, but it is thought to have other non-covalent roles 
(Owerbach et al., 2005).  
 
SUMOylation occurs through an enzymatic cascade resulting in the SUMOylation of 
target proteins at lysine residues. It starts with the transformation of immature SUMO 
molecules into mature proteins presenting a C-terminal diglycine motif which is 
necessary for adenylation by the SUMO E1 activating enzyme. The E1 enzyme can then 
form an E1-SUMO thioester bond before the SUMO is transferred onto the E2 
conjugation enzyme, forming a E2-SUMO thioester bond. Some E2 enzymes can then 
directly transfer the SUMO molecule onto target lysine residues, but usually E3 ligases 
enhance this process and increase the specificity through two mechanisms. They 
either form a complex with the E2-SUMO, forming a scaffold allowing transfer of the 
SUMO residue to the target protein or the E3 ligase can stimulate E2 to release the 
SUMO directly onto a substrate, acting as a sort of catalyst (Gareau and Lima, 2010). 
This general mechanism can be seen in Fig. 18. SUMOylation is a reversible process 
and the SUMO modifications can be removed through SENPS (sentrin-specific 
proteases). These proteases cleave at the C-terminus of SUMO and therefore reverse 






Figure 18 – The enzymatic cascade resulting in the SUMOylation of target proteins at lysine residues. Figure 
adapted from (Johnson, 2004) 
Within mammalian cells, there is only one of each E1 and E2 enzymes which activate 
and conjugate all three of the key SUMO molecules (SUMO1-3), UBA2 and Ubc9 
respectively (Schulman and Harper, 2009; Saitoh et al., 1998). However, there are at 
least two different groups of E3 ligases in mammalian cells, with several distinct 
enzymes in each category. The first category are the SP-RING E3 ligases (similar to 
ubiquitin RING E3 ligases) (Hochstrasser, 2001) which act as the framework to allow 
SENPS 
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the transfer of SUMO from E2 onto the substrate. These SP-RING motif ligases can be 
further sub-divided into PIAS family proteins or ‘others’. The PIAS proteins, for 
example PIAS1, have a shared 400 amino acid sequence at their N terminal as well as 
the shared SP-RING (Kahyo et al., 2001) (Geiss-Friedlander and Melchior, 2007), whilst 
the ‘other’ category ligases, such as NSMCE2, do not share this N terminal domain 
(Geiss-Friedlander and Melchior, 2007). The second main type of E3 ligases have no 
similarity with the ubiquitin ligase pathway and share little sequence similarities, but 
instead act as the catalyst for SUMO release from the E2 enzyme onto the substrate. 
An example of this subset is RANBP2, a protein involved in controlling nuclear 
transport (Pichler et al., 2004). As mentioned previously, SUMO modifications can be 
removed from substrates through the action of SENPS. There are six SUMO-specific 
SENPS encoded within the human genome; SENP1, SENP2, SENP3, SENP5, SENP6 and 
SENP7, which share a 200 amino acid catalytic domain. Each SENP can carry out 
deconjugation and processing of a range of proteins, but often in a specific biological 
process or point in development. For example, SENP2 acts early in embryonic 
development (Nayak and Müller, 2014). 
 
As well as the addition of one SUMO molecule to a protein substrate, mono-
SUMOylation, poly-SUMO chains made up of mainly SUMO-2 and SUMO-3 can form 
on target proteins (Ulrich, 2008). SUMO polymerization occurs through interactions 
between SUMO molecules and the surface of E2 enzymes which allow the chains to 
form (shown in Fig. 19) (Capili and Lima, 2007). The effects of mono and poly 
SUMOylation are different depending on the protein and it widens the range of cellular 




Figure 19 - Diagrammatic representation of the formation of SUMO chains on target proteins using the 
conjugating Ubc9 (E2) enzyme shown in brown.  Figure taken from (Ulrich, 2008) 
 
The importance of SUMOylation has been demonstrated many times, right from 
embryo development through to cell death following trauma (Nacerddine et al., 2005; 
Zhang et al., 2016). One of the main effects of SUMO modifications is to alter the 
activity of the specific protein, either positively or negatively. For example, when the 
protein product of the RGSZ2 gene, a regulator of G protein signaling, RGS GAP, 
becomes covalently SUMOylated, it removes its GTPase-activating protein capabilities, 
regulating the activity of the protein (Garzón et al., 2011). However, it is often not the 
covalent binding of the SUMO residue itself which causes the effects of SUMO 
modification seen in many biological processes. SUMO interacting motifs (SIMs) are 
protein regions which non-covalently interact with SUMO molecules/chains upon 
covalently SUMOylated proteins, causing an effect to take place (Kerscher, 2007). The 
effects of SIM binding can also be demonstrated through the RGS GAP protein, as 
when a SUMO residue covalently bound to another protein, non-covalently binds to 
the RGS GAP RH domain SIM, RGS GAP becomes unable to interact with other G 
protein coupled receptor signaling subunits and carry out its signaling function (Garzón 
et al., 2011). This is an example of how SUMO modifications can affect the functional 
interactions of a protein, but it is also possible that SUMO modifications can affect 
interactions which alter the localization of the proteins within the cell. For example, 
RanGAP1 can become covalently SUMOylated with SUMO-1, which allows it to move 
to and associate with RanBP2 at the cytoplasmic periphery of the nuclear pore 
complex, through its SIM (Mahajan et al., 1997). It is also thought that the Polo-like 
kinase 1 (Plk1)- interacting checkpoint helicase (PICH) locates at the centromere to 
allow for correct chromosome segregation through interactions between its SIM-3 and 
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an unknown covalently modified SUMO protein (Sridharan and Azuma, 2016). SUMO 
modification can also have an impact upon protein stability, as demonstrated by 
NDRG1, the metastasis suppressor protein. Upon SUMOylation by SUMO-2, the 
protein becomes destabilized, affecting the protein function and its concentration 
within the cell (Lee and Kim., 2015). Another SUMO stability mechanism occurs with 
the promyelocytic leukaemia protein (PML), as when it becomes poly-SUMOylated it 
is signaled for its degradation through the ubiquitin pathway (Tatham et al., 2008).  
 
It has been demonstrated that the differing effects of poly-SUMO chains compared to 
individual SUMO modifications may occur as proteins with multiple SIMs within their 
amino acid sequence can bind more securely to the SUMO chains than mono-SUMO 
residues. This may explain how the two types of modification are distinguished and 
how the differences in effects between poly and mono SUMOylated proteins occur, 
giving rise to the wide range of effects noted (Xu et al., 2014). 
 
SUMO modifications play a significant role in maintaining the stability of the genome. 
They are vital for correct chromosome segregation, removal of cruciform structures 
following replication fork collapse, cell cycle progression as well as the important 
checkpoint activation, amongst many other cellular processes (Nacerddine et al., 
2005; Branzei et al., 2006; Seufert et al., 1995). One of the most important genome 
stability roles SUMO modifications have is within DNA damage repair, although how it 
does so is still not well understood. SUMO-1, 2 and 3 all accumulate at the sites of 
double strand breaks in mammalian cells indicating that SUMOylation may play a role 
in regulating the processes which occur following the damage (Galanty et al., 2009). It 
has been found that the central HR protein Rad52 is directly regulated by SUMOylation 
(Altmannova et al., 2010; Sacher et al., 2006), along with other well-known DNA repair 
proteins PCNA, Sgs1 helicase, BLM and WRN (Kawabe et al., 2000; Eladad et al., 2005; 
Hoege et al., 2002; Bermúdez-López et al., 2016). This provides strong evidence that 
SUMO modifications may hold the key to how DNA repair and genome stability 
processes are all coordinated and controlled. SUMO-targeted E3 ubiquitin ligases 
(STUbLs) are also thought to play an important role in genome maintenance. These 
ligases use SIMs to recognize their targets and regulate the levels of SUMOylated 
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proteins within each cell by targeting these proteins for ubiquitin-dependent 
proteasomal degradation (Perry et al., 2008). Limited targets have been found making 
it difficult to make specific judgements but the human STUbL, RNF4, has been shown 
to interact with the human E2 and E3 ligases, indicating that it downregulates SUMO 
signaling as part of its role to maintain the genome (Kumar et al., 2017). 
 
1.10 The SUMO ligase function of the SMC5/6 complex  
 
Two components of the SMC5/6 complex have E3 ligase roles; NSMCE1 as an E3 
ubiquitin ligase and NSMCE2 as an E3 SUMO ligase. These catalytic roles were initially 
proposed following sequence analysis of these subunits by (McDonald et al., 2003), 
where NSMCE1 featured a RING finger motif, suggesting its role as a possible E3 factor 
in ubiquitinylation and NSMCE2 featured a zinc finger similar to the DNA binding 
protein Miz1, indicating its role in SUMOylation. The ubiquitin ligase function of 
NSMCE1 was then confirmed in vitro, through the study of MAGE proteins such as 
MAGEG1 (Nse3 in yeast), where it was demonstrated that whilst NSMCE1 has its own 
weak ligase activity, NSMCE3 promotes and enhances this activity as part of the 
SMC5/6 complex (Doyle et al., 2010). The SUMOylation function of Nse2 was first 
confirmed in S. pombe, before this activity was then replicated in human cells 
(Andrews et al., 2005; Potts and Yu, 2005).  
 
The roles of these ligase subunits have been studied intensely over the past 20 years, 
with their targets and functions still largely unidentified. However, quickly after the 
proteins discovery it was found that the Nse2/NSMCE2 SUMO ligase, in both yeast and 
human cells, had an important function in DNA damage repair and in the avoidance of 
DNA damage during normal mitotic cell division (Potts and Yu, 2005; Andrews et al., 
2005). This led to the suggestion the NSMCE2 SUMO ligase may play a wide role in 
chromosome maintenance and RS recovery. Subsequently much of the research has 
focused upon this area.  
 
In support of this suggestion, mutant Mms21/Nse2 S. cerevisiae cells were shown to 
spontaneously incur DNA damage as well as being very sensitive to RS, which resulted 
 46 
in many cell cycle progression defects and chromosome breakage, possibly due to the 
non-functioning Nse2 SUMO ligase (Rai et al., 2011). Furthermore, several other yeast 
studies have also demonstrated a role for the Nse2 SUMO ligase in RS recovery, 
resolving recombination intermediates such as cruciform structures, produced 
following collapsed replication forks (Chavez et al., 2010; Branzei et al., 2006). As well 
as studies using yeast, there has also been support for the NSMCE2 DNA repair 
function in DT40 chicken cells, where the SUMO ligase ability was shown to be vital for 
DNA repair as well as recovery from RS following exogenous damage, with a strong 
suggestion for a role within HR (Kliszczak et al., 2012).  
 
Primordial dwarfism, has now been determined to be the result of many DNA damage 
response/repair- associated genetic defects (Alcantara and O'Driscoll, 2014). Human 
patients with NSMCE2 mutations, have been described which present with primordial 
dwarfism, along with other defects such as gonadal failure and insulin resistance, 
indicating that the SUMO ligase function of NSMCE2 may be vital for DNA damage 
repair on a whole mammalian system level. The cells from these patients displayed 
increased numbers of micronuclei and nucleoplasmic bridges as well as reduced 
recovery from RS during DNA synthesis. These abnormalities could be reversed 
through the addition of wildtype NSMCE2 but not through the addition of ligase-dead 
NSMCE2, supporting the previous yeast studies that it is specifically the ligase function 
of NSMCE2 which carries out these RS recovery and repair roles. The same research 
group have also found that NSMCE2 knockdowns in Zebrafish produce the same 
dwarfism phenotype seen within the human patients. This again could be reversed 
through re-expression of wildtype NSMCE2 but not the ligase-dead form, further 
indicating that it may be the reduced tolerance to RS due to the removal of the SUMO 
ligase which causes the dwarfism (Payne et al., 2014).  
 
Although there is now fairly strong evidence in support of a genome stability role for 
the NSMCE2 SUMO ligase, to date, only a handful of NSMCE2 SUMOylation targets 
have been identified. Initial studies in S. pombe revealed that Nse2 SUMOylates both 
itself, SMC6 and Nse3, whilst in vitro assays using human NSMCE2 have similarly 
confirmed NSMCE2 autoSUMOylation and modification of SMC6 (Andrews et al., 
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2005) (Potts and Yu, 2005). It has been reported that SMC5 may also be SUMOylated, 
in both yeast and in human cells, but it is not yet clear whether this modification is 
solely NSMCE2 dependent (Bustard et al., 2012; Zhao and Blobel, 2005).  
 
As well as components of the SMC5/6 complex itself, other reported targets of 
NSMCE2 SUMOylation include TRAX, the Sgs-1 -Top3-Rmi1 complex, KU70, Scc1, TRF1 
and TRF2. These targets often support the case that the NSMCE2 SUMO ligase function 
lies within chromosome maintenance and RS repair. For example, the Sgs-1-Top3-
Rmi1 (STR) complex is employed by the cell to remove and repair RS intermediates, 
and its ability to do so is provided by SUMOylation by NSMCE2. Upon SUMOylation, 
the STR complex accumulates at repair sites and is able to form inter-subunit 
interactions, promoting its activity, aiding RS tolerance (Bonner et al., 2016). The 
SMC5/6 complex has also been shown to SUMOylate Scc1, a human subunit of 
cohesin. The SUMOylation of Scc1 by NSMCE2 causes antagonisation of Wap1, 
allowing HR to be carried out within human cells, removing damage and providing 
protection from RS (Wu et al., 2012). As well as this, NSMCE2 is also known to 
SUMOylate the telomere binding proteins, TRF1 and TRF2. These proteins allow 
telomere elongation through HR to occur in a process named alternative lengthening 
of telomeres, often used by malignant cells (Potts and Yu, 2007). 
 
As the range of NSMCE2 targets has only just beginning to be revealed, it is possible 
that nearly all of the genome stability and repair functions of the SMC5/6 may be 
explained through the NSMCE2 SUMO ligase ability. It is possible that the complex may 
act as a caretaker for the whole system, overseeing and directing the process to ensure 
genome stability throughout replication.  
 
1.11 This Thesis  
 
The introduction has outlined the important roles RS and GI play in the development 
and progression of cancer. For this reason, mechanisms for repairing genetic damage 
and resolving replication stress are vitally important, acting as a surveillance system to 
preserve genome integrity. A key protein complex thought to be involved in this 
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process is the evolutionarily conserved SMC5/6 structural maintenance of 
chromosomes complex, however its specific role remains unclear. Previous studies 
have indicated that the ligase activity of the NSMCE2 subunit of SMC5/6 is critically 
important for the function of the complex, therefore this study aimed to characterize 
human cell lines mutated for NSMCE2 to explore this further.  
 
Prior to the commencement of this study, two NSMCE2 knockout cell lines (N2A KO 
and N2B KO) were created through CRISPR-Cas9 gene targeting using LifeTech GeneArt 
CRISPR gene editing kit. The mutations were directed against two different sequences 
within exon 1 of the NSMCE2 open reading frame. For the N2A KO cell line, the 
targeted sequence (tgtatcaactctggtatggac) was at 97-117bp, whilst for N2B KO, the 
targeted sequence (ggacgttccagttcaaattc) was at 7-26bp. To complement these cell 
lines, NSMCE2 knockout cell lines with wildtype NSMCE2 re-expression (N2 WT) along 
with NSMCE2 knockout cells expressing ligase-dead NSMCE2 (N2 R) were also created. 
These rescue clones were derived from both respective knockout cell lines by stable 
transfection with wildtype NSMCE2 or NSMCE2 RING mutant in pCl-neo mammalian 
expression vector.  
 
Following their creation, proliferation assays were then carried out, as shown for the 
N2A cell lines in Fig. 20. These data demonstrate that loss of the NSMCE2 subunit 
causes a moderate proliferation defect that can be rescued by re-expression of wild 
type NSMCE2. Surprisingly, expression of catalytically inactivated NSMCE2 
exacerbates this proliferation defect. These data suggest that the observed 
proliferation defect is due to the specific loss of NSMCE2 or its catalytic activity only.  
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Figure 20 - Cell line proliferation assay for each the CRISPR-Cas9 genome edited cell lines; NSMCE2 knock out (N2A 
KO), NSMCE2 knockout with wildtype NSMCE2 re-expression (N2A WT1 and N2A WT2) and NSMCE2 knockout 
cells with ligase-dead NSMCE2 re-expression (N2A R2 and N2A R3), created prior to the commencement of this 
study.  
 
 The aim of this project was to further characterize these NSMCE2 cell lines with the 
intention of determining the genome maintenance and repair functions of NSMCE2 
and its SUMO ligase. Experiments were first carried out to validate the cell lines; 
assessing the expression level of each of the SMC5/6 components and the association 
of those components before further analysis of their ability to progress through the 
cell cycle, focusing on DNA replication and chromosome segregation. This enabled us 
to ascertain whether NSMCE2 and its SUMO ligase play a role within these processes. 
Additionally, a protocol was developed with the aim of identifying specific 



















Chapter 2: Materials and Methods 
 
Composition of solutions used  
Solution Composition 
Resuspension Buffer (for total cell 
extracts) 
50mM Tris pH7.5, 150mM NaCl, 1mM 
MgCl2 
Phosphatase Inhibitor Resuspension 
Buffer (for total cell extracts) 
50mM Tris pH7.5, 150mM NaCl, 1mM 
MgCl2, 20mM NaF, 10mM β-
glycerophosphate, 2mM NaaVO3 
Lysis Buffer (for routine total cell 
extracts and Immunoprecipitation) 
50mM Tris pH7.5, 150mM NaCl, 1mM 
MgCl2, 0.1% SDS, 1μl/ml Base muncher 
(Expedeon®), Protease inhibitor cocktail 
(Expedeon®) at 1/100. For 
immunoprecipitation, 0.1% NP40 was 
used instead of 0.1% SDS.  
5x Loading Buffer for SDS-PAGE 
electrophoresis 
0.25% bromophenol blue 0.5M 
dithiothreitol, 50% glycerol, 10% SDS 
SDS-PAGE running buffer 24.8mM Tris-base, 192mM Glycine, 
0.1% SDS 
Transfer Buffer (for semi-dry transfer) 48mM Tris-base, 39mM Glycine, 0.038% 
SDS, 20% Methanol 
PBS 8mM Na2HPO4, 15mM KH2PO4, 3mM 
KCl, 137mM NaCl, pH 7.3 
PBS-T PBS plus 0.02%, 0.1% or 0.5% Tween 
Blocking Buffer 1  5% milk powder in PBS-T (0.1 or 0.5%) 
Blocking Buffer 2 3% BSA in PBS-T (0.1%) 
Blocking Buffer 3 1x Casein blocking buffer (Sigma Aldrich 
Ò) 
ECL Reagent 20ml of 100mM Tris pH 8.0 with 6μl 
Hydrogen Peroxide (30% solution), 50μl 
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90mM p-coumaric acid, 100μl 250mM 
luminol 
Stripping Buffer 200mM glycine pH2, 0.1% SDS 




PBS with 0.1% TritonX-100 
Immunofluorescence Antibody Buffer 0.5% BSA in PBS 
Biotin Stock Solution 1mM Biotin dissolved in Culture 
Medium 
SUMO Lysis Buffer 8M Urea, 1% SDS, 60mM N-
ethylmaleimide, Protease Inhibitor 
Cocktail (Expedeon®) at 1/100 in 1xPBS  
SUMO Binding Buffer 3M Urea, 1M NaCl, 0.25% SDS in 1xPBS 
SUMO Wash Buffer 1 (WB1) 8M Urea, 0.25% SDS in 1xPBS 
SUMO Wash Buffer 2 (WB2) 6M Guanidine Hydrochloride in 1xPBS 
SUMO Wash Buffer 3 (WB3) 6.4M Urea, 1M NaCl, 0.2% SDS in 1xPBS 
SUMO Wash Buffer 4 (WB4) 4M Urea, 1M NaCl, 10% Isopropanol, 
10% Ethanol, 0.2% SDS in 1xPBS 
SUMO Wash Buffer 5 (WB5) 8M Urea, 1% SDS in 1xPBS 
SUMO Wash Buffer 6 (WB6) 2% SDS in 1xPBS 
SUMO Elution Buffer 4x Loading Buffer for SDS-PAGE 
electrophoresis, 200mM DTT 
SUMO Elution Buffer 2  2% SDS, 10mM Biotin, 8M Urea in 
1xPBS 






















































































































































































































Secondary antibodies used  
Secondary Antibody Host Species Supplier 
Anti-Mouse HRP Rabbit Dako 
Anti-Rabbit HRP Goat Dako 
Alexa Fluor 633  Goat Invitrogen 
 
2.1 Molecular Biology Techniques 
 
2.1.1 Transformation of Plasmid into DH5a competent cells.  
 
For transformation, one 50µl aliquot of DH5a cells was thawed on ice, before 1μl 
plasmid DNA was added and incubated on ice for 30min. The cells were heat shocked 
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for 20-30 secs at 42°C before being incubated for a further 2 min on ice. Transformed 
cells were plated and incubated overnight on selective agar plates with Ampicillin (100 
μg/ml) at 37°C.  
 
2.1.2 Growth of E. coli in liquid cultures 
 
To expand the quantity of plasmid DNA before harvesting, E. coli colonies grown 
following transformation, were inoculated into 100ml LB media containing 100μg/ml 
carbenicillin before incubation at 37°C overnight.  
 
2.1.3 EndoFree MidiPrep  
 
To harvest and purify plasmid DNA from liquid bacterial cultures, midipreps were 
carried out using Qiagen-tip 100 materials according to the manufacturer’s 
instructions, with a few minor adjustments. Following isolation of DNA-containing 
supernatant after addition of P3, DNA was precipitated by addition of 10ml 
isopropanol and centrifugation (5000rpm, 30min). To remove any endotoxins, the 
DNA was re-suspended in 0.5ml TE with 4.5ml QBT containing 10% TritonX-100 and 
incubated at 4°C for 30min before being applied to the Qiagen column. The final 
plasmid DNA pellet was re-suspended in 400µl Buffer TE.  
 
2.1.4 Determining DNA Concentration 
 
To quantify the concentration of DNA, a spectrophotometer, reading dsDNA settings, 
was used to measure absorbance (A260). For each sample, 2µl of DNA was added to 
58µl dH2O, mixed, and compared to a negative control.  
 
2.2 Protein Techniques  
 
2.2.1 Total cell protein extract preparation 
 
To analyse the protein content of various cell samples, total cell protein extraction 
took place. Two methods were routinely used for protein extraction; standard total 
cell extract lysis or direct cell lysis.  
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Standard total cell extract lysis – For general total protein analysis by SDS-PAGE, 
standard cell lysis was carried out. Each cell sample was spun down (4k, 1min) and 
washed in 1ml PBS. Following a further 4k spin, pellets were lysed in 100µl lysis buffer 
(per 5x105 cells) for 10min at RT (or 4°C for immunoprecipitation sample preparation). 
Extracts were clarified through centrifugation (13k, 5min), Bradford assay sample 
taken and the remaining supernatant boiled at 95°C, 3min following addition of 25µl 
5x SDS-PAGE loading buffer.  
 
Direct cell lysis – When it was necessary to minimize any alteration to the cell samples 
during extract preparation, eg. loss of protein phosphorylation, direct cell lysis was 
carried out. Cells were counted and an equal number collected. Each sample was spun 
down (4k, 1min) and washed in 1ml cold PBS before being re-suspended in 100µl of 
either cold Resuspension Buffer or Phosphatase Inhibitor Resuspension Buffer (per 
5x105 cells). 25µl 5x SDS-PAGE loading buffer was immediately added and the samples 
boiled (3min, 95°C). Base Muncher (Expedeon®)(1µl per sample, diluted 1 in 5 in 
resuspension buffer) was then added to each sample and incubated for 5-10min (RT) 
before heating for a further 3min (95°C).  
 
2.2.2 Bradford Assay Method 
 
To determine the overall protein concentration of each sample, Bradford assays were 
undertaken. Cell extract samples (1-2µl) were added to 600µl of Bradford Ultra 
reagent (Expedeon) in a cuvette, mixed and analysed (colour change relative to a 




2.2.3 Acetone Precipitation 
 
To concentrate protein for SDS-PAGE gel loading and western blot detection, acetone 
precipitation was carried out. Four volumes of cold acetone (-20°C) were added to 
protein samples and incubated at -20°C (>1h) before centrifugation (13k, 30min.) The 
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protein pellet was washed in 50% acetone before being re-suspended in an 
appropriate volume of buffer for loading.  
 
2.2.4 SDS PAGE Gel Electrophoresis  
 
To separate proteins based on molecular weight, SDS-PAGE gel electrophoresis was 
carried out using Biometraä mini-gel electrophoresis equipment. The resolving gel 
was prepared according to Table 1 and 5.5ml poured between the assembled gel 
plates, before being overlaid with 100µl of butan-2-ol. Once the gel had set (30-40 
minutes), the remaining butan-2-ol was poured off, the stacking gel (Table 2) added 
and the comb inserted. The gel was allowed to set for 20 minutes before being 
transferred to a Biometraä mini-gel electrophoresis tank in SDS-PAGE running buffer.  
The protein extracts (pre-prepared with the addition of 5x SDS-PAGE gel loading 
buffer) were loaded onto the gel and run at a constant voltage of 120V through the 
stacking gel and 160V through the resolving gel until the dye front had run off. 
 
Table 1- Recipes for 10ml SDS-PAGE Resolving gels to be used in SDS-PAGE gel electrophoresis. 









ddH2O 4.6 4.0 3.3 2.6 
30% Acrylamide mix 2.7 3.3 4.0 4.7 
1.5M Tris (pH 8.8) 2.5 2.5 2.5 2.5 
10% SDS 0.1 0.1 0.1 0.1 
10% APS 0.1 0.1 0.1 0.1 









Table 2- Recipe for 3ml SDS-PAGE Stacking gel to be used in SDS-PAGE gel electrophoresis. 
 Volume (ml) 
ddH2O 2.1 
30% Acrylamide Mix 0.5 
1M Tris (pH 6.8) 0.38 
10% SDS 0.03 
10% APS 0.03 
TEMED 0.003 
 
2.2.5 Western Blotting – Semi-Dry Transfer 
 
For western blot detection, proteins were transferred from SDS-PAGE gels to 
nitrocellulose membranes by semi-dry transfer. The western blot materials (3x Filter 
paper and 1x Nitrocellulose membrane) were soaked in transfer buffer before being 
assembled on semi-dry transfer equipment (Bio-Radä). The layers were constructed 
accordingly; two sheets of filter paper, nitrocellulose membrane, SDS-PAGE gel and a 
final filter paper with air bubbles rolled out between each layer during assembly. The 
proteins were transferred at 20V for 50 minutes.  
 
 
2.2.6 Antibody probing of the Nitrocellulose membrane 
 
To allow detection of specific proteins of interest, nitrocellulose membranes were 
probed with specific antibodies. The membranes were first incubated in blocking 
buffer specific for the antibody (see Table 4) for 1h at RT, before incubation in primary 
antibody in the same buffer (for conditions see Table 2). Following this, membranes 
were washed in PBS-T (4x 5min) (tween concentration the same as blocking buffer) 
and incubated in the appropriate secondary HRP-conjugated antibody (see Table 3) 
diluted in Blocking Buffer 1 (1h, RT.) before further washes in the appropriate PBS-T 
(4x 5min). For western blots of immunoprecipitation samples, protein A/G conjugate 
was used instead of secondary antibody to allow for native antibody visualization only.  
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2.2.7 Developing western blots by enhanced chemiluminescence (ECL) 
 
To allow visualisation of antibody-bound proteins, western blots were developed 
through enhanced chemiluminscence (ECL). After washing the nitrocellulose 
membrane in appropriate PBS-T and blotting dry, freshly made ECL reagent was 
applied for 1min. The membrane was again blotted dry and visualized using the Bio-
rad ChemiDoc™ on Chemi Blot settings. 
 
2.2.8 Stripping of Western blot 
 
To allow re-probing of the nitrocellulose membranes, previously bound antibody was 
removed through membrane stripping. The membranes were washed in 10ml of 
stripping buffer (2x 5min) before being washed in PBS-T (0.1%, 3x 5mins).  The 
membranes could then be re-probed with desired antibodies.  
 
2.2.9.1 Preparation of antibody-coupled magnetic beads for immunoprecipitation  
 
To isolate proteins of interest by immunoprecipitation, antibodies were first 
crosslinked to magnetic beads. Protein A-Dynabeads (Invitrogen ™)(50µl) were 
incubated with 10µg SMC6 or control IgG antibody for 2h. at 4°C after a PBS-T (0.02%) 
wash. To facilitate the washes, the beads were immobilized with a magnet. To 
crosslink, beads were washed in 1M borate, incubated with 10mg DMP crosslinking 
agent for 1h, before a final wash in Tris 1.5M pH 8.8. The beads were stored in PBS-T 




Cell extract for immunoprecipitation was prepared through standard total cell extract 
lysis with NP40 detergent (see 2.2.1). Protein concentrations of individual cell extracts 
were determined and 150µg of protein for each cell extract was mixed with each set 
(IgG and SMC6) of prepared Dynabeads (4°C, 2h). After binding, beads were washed 
in PBS-T (0.02%) and the protein eluted in 50µl 0.2M glycine pH2 then immediately 
neutralized with 8µl Tris pH8.8.  
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2.2.10 Detection of SUMOylated proteins through a bioSUMO Strategy  
 
To analyse and isolate SUMOylated proteins within cells, a bioSUMO approach was 
used, adapted from (Pirone et al., 2016). This protocol specifically isolates SUMOylated 
proteins utilizing the strong interaction between biotin and Streptavidin beads. Cells 
to be analysed are initially transfected with a bio-tagged SUMO conjugate expression 
plasmid. As the bio-tagged SUMO becomes expressed, it is rapidly biotinylated by the 
co-transfected E.coli BirA enzyme, due to the bio tag. These SUMO molecules are then 
quickly used by the endogenous SUMOylation system within cells and the biotinylated 
SUMO molecules become conjugated to SUMOylation targets within the cell. This then 
allows for streptavidin-based affinity chromatography to take place due to the biotin 
tags, and the specific isolation of SUMOylated proteins.  
 
Cells to be analysed through this bioSUMO strategy were grown xon 10cm plates to 
70-80% confluency. The cells were then transfected with the appropriate vector (see 
Table 3) (using method 2.3.2) or treated as an untransfected control. 1mM Biotin stock 
was added to each plate to a concentration of 50μM (immediately or up to 24h post-
transfection) and the cells harvested between 24-72h later.  
 
Table 3- Vectors used within the development of the bioSUMO protocol, for the detection of SUMOylated human 


























































To harvest the cell samples, each plate was washed with cold PBS (2x) and the cells 
scraped into a microcentrifuge tube on ice. The cells were pelleted (500g, 5min.) 
before being re-suspended in 0.75ml SUMO lysis buffer per plate. Each sample was 
sonicated to remove viscosity (routinely 4x15s, 18μm) and centrifuged for 20 min 
(13k). The supernatant was collected and added to 3 volumes SUMO binding buffer 
before an extract sample was taken (40μl added to 10μl 5x SDS-PAGE loading buffer). 
Following this, equilibrated (1xPBS and 2x SUMO bind buffer) high capacity 
Neutravidin® agarose resin beads (ThermoFisher Scientific™) were added (13.3μl per 
plate used) to each sample and incubated overnight (RT).  
 
After incubation, the Neutravidin® beads were pelleted through centrifugation (100g, 
5min) and a flow through sample taken (40μl added to 10μl 5x SDS-PAGE loading 
buffer). The beads were then re-suspended and washed in 300μl (per 10cm plate) of 
the following buffers: 2xWB1, 3xWB2, 1xWB3, 3xWB4, 1xWB1, 1xWB5 and 3xWB6. To 
change wash, the beads were either spun at 2k, 30-45secs through a spin column or 
the wash was aspirated off. As the last wash was removed, 50μl SUMO elution buffer 
was added to the beads, vortexed and boiled (99°C, 8mins). The elution mixture was 
vortexed again, spun briefly and boiled for a second time (99°C, 5mins) before the 
elution was collected through a 13k spin for 5 mins.  
2.3 Cell Culture Techniques 
 
2.3.1 Cell Culture Conditions 
 
MRC5-V1 and all other cell lines used within this project were cultured in defined 
medium (see Table 4) at 37°C in 5% CO2. The media within growth vessels was changed 
every 2-3 days when necessary. 
Table 4 -Culture medium used for culturing MCR5-V1 and all other cell lines used in this project. This media was 
stored at 4°C in the dark 
 Volume (ml) 
DMEM/4.5g Glucose with L-glutamine  500 
Foetal Bovine Serum 50 
Penicillin/Streptomycin (Gibco®) 5 
. 
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Routinely, cells were grown in 75cm2  flasks however, for many experiments they were 
grown in different sized vessels. The size of each vessel and volume of media required 
can be seen in Table 4. When reaching confluence, cells were split and sub-cultured 
allowing for further growth. To do this, the media was aspirated from the cells before 
washing in PBS and incubation in 0.5% trypsin solution (5% trypsin in PBS) (Gibco®) 
(see Table 5) at 37°C until the cells were in suspension. The cells were then spun 
through an equal volume of fresh media (500rpm) to remove the trypsin and re-
suspended in an appropriate volume of medium. Cells could then be put back into the 
growth vessels at an appropriate concentration to allow growth. Where desired, cells 
were counted using a haemocytometer.  
 
Table 5– Description of each growth vessel used to grow MRC5-V1 as well as the other cell lines within this 
project. 
Size of vessel Volume medium 
required (ml) 
Volume of Trypsin 
required (ml) 
Approx. Cell Yield  
Medium Flask 
(75cm2) 
15 5 7x107 
Small Flask 
(25cm2) 
5-7 3-4 2.5x106 
10cm Dish 10-14 4 5.5x106 
6cm Dish 4-5 2-3 2x106 
6 well plate 4 1-2 9.5x105 
12 well plate 2 1 3.8x105 
24 well plate 1 0.2-0.5 1.9x105 
 
Cells were frozen (-80°C or in liquid nitrogen for longer term storage) in cryovials, at 
approximately 1-2 x106/ml, in medium containing 10% DMSO. Once removed from the 
freezer or liquid nitrogen, cells were quickly thawed within a 37°C waterbath and spun 
through 5ml medium (500rpm, 5min) before being transferred into an appropriate 




2.3.2 Transfection  
 
 In order to allow expression of specific proteins, expression plasmids were transfected 
into mammalian cells. Cells to be transfected were routinely grown on a 10cm plate, 
in antibiotic-free medium, to 70-80% confluency and were transfected using FuGENE® 
HD Transfection Reagent. For each plate, 18μg plasmid DNA was mixed with 1ml 
Serum-free media before the addition of 50μl FuGENE®. This was mixed thoroughly 
and incubated at RT for 15-20min. Following incubation, this transfection mix was 
added drop-wise to each plate and gently rocked to enable even distribution.  
 
2.3.3 Fluorescent Activated Cell Sorting (FACS) 
 
Cells to be analysed by FACS were harvested, counted and a roughly equivalent 
number collected from each sample (»1x106). The cells were then washed in cold PBS, 
centrifuged (200G, 10min) and re-suspended in 0.5ml PBS, before being added drop-
wise to 4.5ml 70% ethanol (4°C) whilst being vortexed. Fixed cells were then stored at 
4°C for at least 1h before use. 
 
To hydrate the cells in preparation for FACS analysis, fixed cells were spun (200G, 
10min) and re-suspended in 5ml cold PBS. The hydrating cells were incubated at RT 
for 20 min before being re-suspended in an appropriate volume of PBS (1ml/1x106 
cells) containing 5µg/ml Propidium Iodide and 100µg/ml RNase. After 30 min 
incubation at 4°C, FACS analysis was then undertaken using a Beckman Coulter 
CytoFLEX™ Flow Cytometer with CytExpert™ Software. The number of cells analysed 
was dependent on each specific experiment. These are shown in each results figure.  
 
2.3.4 Immunofluorescence  
 
For antibody staining and immunofluorescence analysis, cells were grown on glass 
coverslips within a 24 well plate until 80% confluency. The coverslip-adhered cells 
were then washed with warm PBS, fixed in 4% formaldehyde in PBS (15min, RT) and 
washed twice more with PBS (5min, RT). The cells were permeabilised through 
incubation with the immunofluorescence permeabilisation buffer (5min, RT), washed 
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in PBS (2x5min, RT), then incubated in immunofluorescence blocking buffer for 1h, RT 
within a humid light-tight box. The coverslips were then incubated in anti-tubulin 
antibody (Cell Signalling Technology®) diluted in Immunofluorescence antibody buffer 
overnight at 4°C. Following incubation, the coverslips were washed in PBS (3x5min, 
RT), incubated with the secondary antibody (Alexa Fluor 633 anti-rabbit IgG) (1h, RT, 
in the dark), followed by three more PBS washes (3x5min, RT). The coverslips were 
mounted onto glass microscope slides using DAPI mounting solution (Vectashield®) 
and then stored at 4°C in the dark until required. The cells were visualised and analysed 
using Zeiss ZEN software a confocal microscope.  To analyse cell size, the largest linear 
















Chapter 3: Results  
 
3.1 Validating the NSMCE2 cell lines 
 
Prior to the start of this project, several NSMCE2 mutant cell lines were generated in 
this laboratory. These cell lines comprise NSMCE2 knockouts (N2AKO and N2B KO), 
NSMCE2 KO with wild type NSMCE2 expression restored (N2A WT1, N2A WT6 and N2B 
WT3), and NSMCE2 KO cells with stably expressed ligase-dead NSMCE2 (N2A R2, N2A 
R3 and N2B R2). Very little previous work had been undertaken in order to validate 
these NSMCE2 cell lines, other than the proliferation assays shown in section 1.11. 
Before any further analysis could be undertaken, it was vital to confirm the 
appropriate expression of NSMCE2 in each cell line and determine the effects of these 
NSMCE2 mutations on the rest of the SMC5/6 complex. 
 
3.1.1 Analysis of SMC5/6 component expression within the NSMCE2 cell lines 
 
In order to determine whether the expression of each of the SMC5/6 components was 
as expected within each of the NSMCE2 mutant cell lines, expression analysis was 
carried out. Previous work has shown that the human SMC5/6 complex contains six 
key components; SMC5, SMC6, NSMCE1, NSMCE2, NSMCE3 and NSMCE4 (Taylor et 
al., 2001; Taylor et al., 2008; Harvey et al., 2004; Potts and Yu, 2005), so it was vital 
that expression of these components was evaluated within each of the NSMCE2 cell 
lines, with only the knockout cell lines expected to not express NSMCE2. 
 
To investigate this, total cell extracts were prepared, as described in section 2.2.1, 
from each of the NSMCE2 mutant cell lines, along with the parental MRC5-V1 cells, 
and analysed by western blotting. Antibodies were used to detect each of the SMC5/6 
components along with GAPDH which served as the loading control. The results, 
shown in Fig. 21, demonstrate that in both the N2A KO and N2B KO cell lines, the 
NSMCE2 knockout has been successful, with NSMCE2 expression apparently 
abolished. In both cases, expression of the other SMC5/6 components was unaffected. 
In addition, the results show that expression of NSMCE2 has been sucessfully restored 
in the wild type NSMCE2 corrected cells (N2A WT1, N2A WT6, N2B WT3), although 
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marginally overexpressed compared to the MRC5 control cells. Ligase-dead NSMCE2 
is expressed at comparable levels in N2A R2 and N2A R3, and at a slightly reduced level 
in N2B R2. As expected, the expression of the other SMC5/6 components within the 
corrected cell lines (ligase dead or wild type NSMCE2) is also unaffected. This data 
confirms the validity of the NSMCE2 cell lines in terms of SMC5/6 component 
expression. From this point forward, the experiments presented focus on the 
NSMCE2A cell lines, hereafter referred to as the NSMCE2 cell lines. 
 
 
3.1.2 Analysis of SMC5/6 complex formation in the NSMCE2 mutant cell lines 
 
Since the expression of the SMC5/6 components within the NSMCE2 cell lines was as 
expected, it was important to discover whether loss of the NSMCE2 protein in its 
entirety, or the loss of only its SUMO ligase activity, affected the structure of the 
complex. In yeast, it has been found that the NSMCE2 component only interacted with 
SMC5 within the SMC5/6 complex (Duan et al., 2009; Andrews et al., 2005; Sergeant 
et al., 2005). Therefore, it was expected that the loss of this protein component would 
not make a significant difference to the overall integrity of the SMC5/6 complex, with 
the remaining components still able to associate. To confirm this, 
A B 
Figure 21-  Western blot showing expression of SMC5/6 components in A) wild type (MRC5) and NSMCE2 
knockout (N2AKO) cells as well as N2A KO cells following re-expression of wild type NSMCE2 (N2Awt1, N2Awt6) 
or ligase-dead NSMCE2 (N2AR2, N2AR3) and in B) wild type (MRC5), NSMCE2 knockout (N2BKO), and N2B KO 
cells following re-expression of wild type NSMCE2 (N2Bwt3) or ligase-dead NSMCE2 (N2BR2). GAPDH is used 
as the loading control. This experiment was performed several times before the commencement of this 




immunoprecipitation assays (see method 2.2.9.2) were carried out. The SMC5/6 
complex was immunoprecipitated from cell extracts prepared from MRC5, N2A KO 
and N2A KO cells expressing wild type NSMCE2 (N2A WT1) or ligase dead NSMCE2 
(N2A R2), using anti-SMC6 antibodies (or non-specific IgG as a negative control). The 
input extract samples and the immunoprecipitated proteins were then analysed by 











The data presented in Fig. 22 (right panel) demonstrate that immunoprecipitation of 
SMC6 results in co-immunoprecipitation of the entire complex when either wild type 
or ligase-dead NSMCE2 is present. Moreover, even in the absence of NSMCE2 
expression, the remaining components of the complex are immunoprecipitated along 
with SMC6, confirming that the expression of the NSMCE2 protein is not required for 
association of the remaining SMC5/6 complex components. No complex components 
were immunoprecipitated on the IgG-bound beads confirming that 
immunoprecipitation of the SMC5/6 components is specific to their association with 
SMC6 and the SMC6 antibody. These results indicate that all further data collected 
using the NSMCE2 mutant cell lines will be specific to the loss of the NSMCE2 
component or is activity and not due to loss of the integrity of the entire SMC5/6 
complex.  
Figure 22 -  Western Blot showing results of an Immunoprecipitation assay on the NSMCE2A cell lines; Wild type 
(MRC5), NSMCE2 knockout (N2AKO) as well as N2A KO cells following re-expression of the wild type NSMCE2 (N2A 
wt1) or ligase-dead NSMCE2 (N2AR2). 75µg of cell protein extract was used in each immunoprecipitation assay 
and 1/5th used as the extract sample. IgG concentration is used as the antibody control and GAPDH as the loading 
control for the extract samples. 
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 3.1.3 Cell Cycle Analysis of each NSMCE2 cell line 
 
It was previously identified that both the NSMCE2 knockout and ligase-dead cells 
proliferated at a slower rate (see proliferation data in section 1.11). To determine 
whether this reduced proliferation rate related to slowed progression through the cell 
cycle, cell cycle analysis was performed through Fluorescent activated cell sorting 
(FACS). This would aid determination of whether these slow proliferating cell lines 
were having problems progressing through a specific cell cycle phase, through the 
entire cell cycle (such as due to a metabolic defect) or due to extensive cell death. Cells 
of each NSMCE2 cell line were fixed and the cellular DNA stained with propidium 
iodide before cell cycle analysis was undertaken using Beckman Coulter CytoFLEX™ 
Flow Cytometer with CytExpert™ Software as described in 2.3.3. The results of this 
analysis are presented in Fig. 23.  
 
Figure 23 - FACS analysis showing the cell cycle proportions at a specific time point for each of the NSMCE2A cell 
lines; wild type (MRC5), NSMCE2 knockout (N2AKO) and N2A KO cells following re-expression of wild type NSMCE2 
(N2A WT) or ligase dead NSMCE2 (N2A R2 and N2A R3). The cells were stained with Propidium Iodide to visualise 
the DNA content. 10,000 cells analysed per cell line. The marked  cell cycle stages are to be used  as guidelines only. 
This experiment was repeated frequently throughout the project in order to ensure the reliability of each cell line. 
This figure demonstrates a representative example.  
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The data presented in Fig. 23 illustrate that the slowed proliferation rate of the 
NSMCE2 knockout cells may be due to a difficulty moving through S phase of the cell 
cycle, with a noticeably reduced proportion of cells within G1 and an increased S/G2 
population. Moreover, the re-expression of wild type NSMCE2 in the corrected cells 
(N2A WT1) restores the FACS profile to trace the one attained by MRC5-V1 cells almost 
completely, as in the proliferation assay, indicating that the NSMCE2 knockout cell 
cycle defect is specific to NSMCE2 component loss, rather than an off-target effect of 
the CRISPR Cas9 modification.  
The FACS profile of both NSMCE2 ligase-dead cell lines reveals that their ability to 
move through the cell cycle is significantly more affected than the NSMCE2 knockout 
cells. The population of cells are predominantly accumulated in mid-late S phase, 
suggesting that these cells are having difficulties in completing DNA replication and 
proceeding to G2/M. As well as this, there is a significant population of cells with >4N 
DNA content. This suggests that when these cells are able to finish replicating their 
DNA, they are then unable to effectively separate the replicated chromosomes into 
two new daughter cells, possibly due to issues arising during S phase, but instead begin 
to re-replicate their DNA without effective chromosome segregation, giving a >4N 
population of cells. Although a proportion of the N2A R2 and R3 cell populations 
expressing ligase-dead NSMCE2, must eventually replicate and segregate their DNA to 
continue proliferation, both of these processes appear compromised, perhaps 
explaining their extremely slowed proliferation rate. It is possible that the S phase 
delay in both the NSMCE2 knockout and ligase-dead cell lines is caused by the 
activation of the DNA damage or replication checkpoints, as this would halt the cells 
moving through S phase. Nevertheless activation of these checkpoints would not 
explain the >4N ligase-dead population, suggesting another process may be involved.  
 
What is most interesting about this data, is that the loss of the entire NSMCE2 protein 
results in a cell cycle profile more closely related to wildtype MRC5 than that following 
re-expression of a catalytically inactive version of this protein. This trend is 
corroborated by the proliferation assay data. This indicates that the catalytically-
inactivated NSMCE2 protein may exert a dominant-negative effect, where the ligase-
dead protein acts antagonistically, possibly interacting with the normal proteins within 
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the cell and blocking their functions. This will be important to consider when 
interpreting all further data.  
 
3.2 The activation of the Damage and Replication checkpoints 
 
3.2.1 Validation of Damage and Replication checkpoint antibodies  
 
The reduced proliferation seen within the knockout and ligase dead NSMCE2 cell lines 
has been associated with slow progression through S phase, especially in N2A R2 and 
N2A R3, as shown in Fig. 23. This suggests that NSMCE2 ligase activity is important for 
S phase progression. There are two checkpoints used by cells which can also halt 
progression through S phase; the DNA damage checkpoint and the replication 
checkpoint (González Besteiro and Gottifredi, 2015; Chehab et al., 2000). Since the 
SMC5/6 complex has been strongly linked to repair of damage and recovery from RS 
since its discovery (Lehmann et al., 1995; Nasim and Smith, 1975; Andrews et al., 2005; 
Zhao and Blobel, 2005), it was important to discover whether the altered progression 
through S-phase observed in our NSMCE2 mutant cell lines was at all associated with 
the activation of either of these checkpoint mechanisms. For these reasons, we 
wanted to test the NSMCE2 cell lines for activation of both the DNA damage and 
replication checkpoints, during normal replication and following exogenous stress.  
 
Key molecules which are phosphorylated and act early in the DNA damage checkpoint 
are ATM and Chk2 (Chaturvedi et al., 1999), whilst ATR and Chk1 act mainly in 
response to RS and the single strand DNA which forms (Zou and Elledge, 2003). 
Phosphorylation of these important kinases denotes the activation of the two 
checkpoints respectively, and so we tested various antibodies against the 
phosphorylated forms of these checkpoint proteins (a-ATMpS1981, a-Chk2pT68, a-
ATRpS428, a-Chk1pS345) for use in our subsequent analysis of NSMCE2 mutant cells. 
In order to test the detection ability of these phospho-antibodies, MRC5 cells were 
treated with a variety of genotoxic agents (5µM Etoposide (16h), 200 or 10µM H2O2 
(1h) or 25, 10 or 2.5nM Neocarzinostatin (NCS) (1h) before total cell extracts were 
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prepared using the phospho-protein direct cell lysis method (see method 2.2.1). 50µg 
of total protein extract  
was resolved through SDS-PAGE gel electrophoresis and western blotted (see 
methods 2.2.4 and 2.2.5) with each of the four antibodies. The result are shown in 
Fig. 24.  
 
Figure 24 - Western blot to test the detection ability of ATM, ATR, Phospho-Chk1 and Phospho-Chk2 following 
damage treatment of wild type MRC5 cells. Cells were treated with either 5µM Etoposide (Etop), 200 or 10µM H2O2 
or 25, 10 or 2.5nM Neocarzinostatin (NCS). 50µg of total protein cell extract was resolved through SDS-PAGE gel 
electrophoresis for each treatment. 
 
Although the a-ATRpS428 antibody detected two bands in both untreated and treated 
cell extracts, it was not clear if either band represented phosphorylated ATR since 
there was no apparent increase in signal following treatment with agents that cause 
RS such as etoposide. For this reason, it was subsequently discounted from further 
testing and experiments. Moreover, the signal created by the a-Chk1pS345 antibody 
also does not appear to be quantitatively different following treatment with RS agents 
compared to the control extract. However, it was hoped that with the resolution of 
more protein, it may possibly generate a stronger more quantifiable a-Chk1pS345 
signal. Conversely, the a-ATMpS1981 antibody showed more promise, with a relative 
increase in phosphorylated ATM (upper band indicated by arrow) within the damage 
treated samples compared to the controls. The upper band is more intense following 
etoposide treatment or treatment with increased amounts of NCS.  The expected 
pattern of stronger kinase activation with greater amounts of genotoxic agent 
treatment was also demonstrated following use of the a-Chk2pT68 antibody, 
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mirroring the pattern created with ATM as expected. Additional experiments were 
undertaken to further test and validate the detection abilities of these antibodies. 
 
To further assess the detection of phosphorylated checkpoint proteins using these 
phospho-specific antibodies, MRC5 were treated with either 2.5nM camptothecin 
(CPT) (16h), 2mM hydroxyurea (HU) (16h), or 5µM etoposide (16h). Total cell extracts 
were prepared and 75µg was resolved through SDS-PAGE gel electrophoresis before 
western blotting with a-ATMpS1981, a-Chk1pS345, a-Chk2pT68 and a-p53pS15 
antibodies. It has been known for a long time that p53 is a key player in the DNA 
damage response, which becomes phosphorylated by ATM following the production 
of damage (Kastan et al., 1992). In these experiments, the phosphorylation of p53 was 
utilised to determine the presence of DNA damage in each of the NSMCE2 cell lines. 





As clearly shown in Fig. 25, the phospho-p53 antibody clearly detected the 
phosphorylated form of p53 in each of the damage treated cell extracts, relative to the 
untreated control, and so could be used to detect levels of DNA damage in future 
experiments. However, results for the other antibodies were less clear cut. As shown 
in Fig. 25, the a- ATMpS1981 antibody was found to be unusable due to the extensive 
Figure 25 - Western blot to test the detection ability of ATM, phospho-Chk1, phospho-Chk2 and phospho-p53 
following damage treatment of wild type MRC5 cells. Cells were treated with either 2.5nM Camptothecin 
(CPT), 2mM HydroxyUrea (HU), or 5µM Etoposide before 75μg of total protein extract was resolved through 



















background signal generated and so it was discounted from use in further 
experiments. The signal generated by both the a-Chk1pS345 and a-Chk2pT68 
antibodies following CPT and HU treatment was greater than in the control sample 
and so, despite some variability noted in subsequent experiments, it was determined 
that the antibodies were functional, and could be used to determine the activation 
state of the damage and replication checkpoints in each of the NSMCE2 cell lines.  
 
3.2.2 Assessment of Damage Accumulation within the NSMCE2 cell lines 
 
The slowed cell cycle progression noted in the NSMCE2 mutant cells could be a 
consequence of DNA damage arising in the absence of NSMCE2 ligase activity. DNA 
damage can arise as a consequence of RS and endogenously arising DNA damage 
could, in turn, hinder DNA replication, by interfering with fork progression. DNA 
damage can also prevent cell cycle progression by activating the DNA damage 
checkpoint, allowing cells to repair the damaged DNA (Reviewed in: (Zannini et al., 
2014)). Therefore, we wanted to examine the possibility that DNA damage was 
accumulating within the NSMCE2 mutant cell lines and so hindering cell cycle 
progression.  To do so, we analysed two markers of DNA damage within each of our 
NSMCE2 cell lines, the phosphorylated forms of H2AX (g-H2AX) and of p53 (a-
p53pS15). H2AX is a variant of the histone H2A protein found within the nucleosome 
core and its phosphorylation is a commonly used marker for DNA damage. Following 
replication stress and genetic damage, particularly dsbreaks, H2AX is phosphorylated 
at Ser139 by ATM and ATR (Rogakou et al., 1998; Burma et al., 2001; Ward and Chen, 
2001). The phosphorylated form of p53, as discussed earlier, is also activated following 
DNA damage by ATM (Kastan et al., 1992) to allow for a wide range of DNA repair 
responses, or apoptosis when repair cannot occur (Williams and Schumacher, 2016).  
 
To determine the level of these DNA damage markers within each of the N2A cell lines, 
equal amounts of total cell extract (see method 2.2.1) from each cell line (MRC5, MRC5 
(treated with 5µM etoposide (1h), N2A KO, N2A KO with wild type NSMCE2 (N2A WT1) 
and N2A KO with ligase dead NSMCE2 (N2A R2 and N2A R3)) were analysed by western 
blotting using antibodies against both g-H2AX and a-p53pS15, along with relevant 
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controls (a- histone H3, a-p53 and a-GAPDH). These experiments were repeated 
three times and a representative blot can be seen in Fig. 26.  
  
As shown in Fig. 26, there is no evidence to suggest that there are increased levels of 
DNA damage in the NSMCE2 knockout cell line over the background levels of damage 
noted within both the wild type MRC5 cells and the NSMCE2 KO with wild type 
NSMCE2 re-expression. This indicates that the slightly reduced S/G2 phase progression 
and reduced proliferation rate noted in the NSMCE2 knockout cells is not due to 
increased levels of DNA damage. However, it is clear that expressing the ligase-dead 
form of NSMCE2 does cause increased endogenous DNA damage compared to the wild 
type cell lines, as shown by increased expression of the phosphorylated forms of both 
H2AX and p53. This suggests that increased DNA damage may contribute to the 
reduced S phase progression seen in cells with catalytically inactivated NSMCE2.  
 
3.2.3 Activation of the Damage checkpoint by the NSMCE2 cell lines 
 
Since it is clear that there is an increase in DNA damage within the NSMCE2 ligase-
dead cell lines, activation of the DNA damage checkpoint could be contributing to 
slowed S phase progression in these cells. To determine whether this could be the 
case, we decided to analyse Chk2 phosphorylation as a marker for activation of the 
ATM-dependent DNA damage checkpoint response (Chaturvedi et al., 1999).  
 
Figure 26 - Western showing the expression of A) phospho-H2AX and Histone H3 and B) phospho-p53, p53 and 
GAPDH in 5µM etoposide (1h) treated MRC5 wild type, untreated MRC5 wild type and untreated NSMCE2 knockout 
(N2AKO) cells as well as N2A KO cells following re-expression of wild type NSMCE2 (N2A wt1) or ligase dead NSMCE2 
(N2ALD1 and N2A LD2). Loading controls are A) Histone H3 and B) GAPDH. The etoposide treated MRC5 cells act as 
a positive control for the DNA damage response. 7.5x104 cells per sample. Representative of 3 independent repeats.  
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As in the previous experiment, equal amounts of total cell extract (method 2.2.1) from 
each of the NSMCE2 cell lines; MRC5, N2A KO, N2AWt1, N2AR2 and N2A R3 as well as 
MRC5 cells treated with 5µM etoposide, were analysed by western blotting with 
antibodies against phosphorylated (a-Chk2pT68) and un-phoshorylated forms of Chk2 
as well as GAPDH as the loading control. The results of the western blot can be seen 
in Fig. 27.  
 
 
As expected, Fig. 27 illustrates that there is no increased activation of the DNA damage 
checkpoint within the NSMCE2 knockout cell line compared to both the control MRC5 
and NSMCE2 knockout cells with wild type NSMCE2 re-expression, as shown by the 
level of phosphorylated Chk2. This supports the previous data which showed no 
phosphorylation of the DNA damage markers, g-H2AX and p53pS15, indicating that it 
is unlikely that increased DNA damage or activation of the damage checkpoint is the 
cause of the reduced proliferation rate seen within the NSMCE2 knockout cell lines. 
Moreover, unexpectedly, the NSMCE2 knockout cell line has a decreased level of 
unphosphorylated Chk2 compared to the other cell lines. This may explain why there 
is no increase in phosphorylated Chk2 as there is less overall Chk2 to become 
phosphorylated. This indicates that NSMCE2 may be involved with the activation of 
the DNA damage checkpoint at an early stage, and this cell line may have difficulty 
activating their DNA damage checkpoint at all.  
 
Figure 27 -Western blot showing the expression of phospho-chk2, chk2 and GAPDH in 5µM etoposide (1h) treated 
MRC5 wild type, MRC5 wild type and NSMCE2 knockout (N2AKO) cells as well as N2A KO cells following re-
expression of wild type NSMCE2 (N2A wt1) or ligase dead NSMCE2 (N2ALD1 and N2A LD2). GAPDH is used as the 
loading control. 7.5x104 cells per sample. This experiment was independently repeated three times. This figure 
demonstrates a representative example.  
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Conversely, both cell lines expressing the ligase-dead NSMCE2 do exhibit some Chk2 
phosphorylation, so indicating activation of the DNA damage checkpoint in the 
presence of the DNA damage noted in Fig. 26. The activation of Chk2 seems to 
correlate with the level of damage accrued, as although the a-Chk2pT68 band is not 
as intense within the ligase-dead cell lines compared to the etoposide treated sample, 
this correlates with the damage accumulation shown in Fig. 26. This seems to validate 
that it may be DNA damage and activation of the DNA damage checkpoint which is, at 
least partly, causing the build-up of NSMCE2 ligase-dead cells within S phase. On the 
other hand, there is an increased level of un-phosphorylated Chk2 within both of the 
ligase-dead cell lines,  suggesting that although there is an increase in phosphorylated 
Chk2 compared to the wild type cell line, there is the same proportion of 
unphosphorylated and phosphorylated Chk2. These data may indicate that the ligase-
dead cell lines may not be phosphorylating Chk2 and activating the checkpoint any 
more than the wild type cell line.  
 
3.2.3 Activation of the Replication Checkpoint by the NSMCE2 cell lines 
 
The second checkpoint which could be activated, causing the slowed progression 
through S phase of the NSMCE2 knockout and NSMCE2 ligase-dead cells, is the 
replication checkpoint. This checkpoint involves the activation and binding of ATR to 
ssDNA following replication stress, which subsequently causes the phosphorylation of 
Chk1 and halting of the cell cycle through the involvement of many other proteins (as 
discussed in the introduction). To determine if this checkpoint activation is the cause, 
we decided to analyse the phosphorylation of Chk1 at Ser345 as a marker for 
activation of the ATR-dependent replication checkpoint. To do so, as in the previous 
experiment, equal amounts of total cell extract (method 2.2.1) from each of the 
NSMCE2 cell lines; MRC5, N2A KO, N2AWt1, N2AR2 and N2A R3 as well as MRC5 cells 
treated with 5µM etoposide, were analysed by western blotting with antibodies 
against phosphorylated (a-Chk1pS345) and un-phoshorylated forms of Chk1 as well as 
GAPDH as the loading control. This experiment was repeated three times and a 




Fig. 28. indicates that, somewhat surprisingly, none of the NSMCE2 cell lines activate 
the replication checkpoint, with no phosphorylation of Chk1 detected in these cell 
lines, as compared with the etoposide-treated MRC5 cells used as positive control. 
This indicates that the slow progression of N2KO and NSMCE2 ligase-dead cells is not 
due to the activation of the replication checkpoint. It is possible that NSMCE2 mutant 
cells do activate the replication checkpoint to an extent that is below the level that we 
can detect, but there is no evidence of substantial checkpoint activation in this assay. 
These findings raised a question as to whether the problems incurred in the NSMCE2 
ligase dead mutants, slowing S phase progression, are not sensed or responded to by 
the replication checkpoint, or whether these NSMCE2 mutant cells are unable to 
activate the replication checkpoint at all.  
 
In order to determine the ability of each of the NSMCE2 cell lines to activate the 
replication checkpoint, each cell line was subjected to replication stress treatment 
with 2mM HU (16h), which should normally activate the replication checkpoint if cells 
have the capacity to do so (Koç et al., 2004). The cells were then analysed by flow 
cytometry (see method 2.3.3) to determine whether the cell cycle was halted at the 





Figure 28 - Western blot showing the expression of phospho-chk1, chk1 and GAPDH in 5µM etoposide (1h) treated 
MRC5 wild type, MRC5 wild type and NSMCE2 knockout (N2AKO) cells as well as N2A KO cells following re-
expression of wild type NSMCE2 (N2A wt1) or ligase dead NSMCE2 (N2ALD1 and N2A LD2). GAPDH is used as the 
loading control. 7.5x104 cells per sample. This experiment was independently repeated three times. This figure 




Figure 29 - Flow cytometry analysis showing the cell cycle proportions of untreated Wild type MRC5 cells, NSMCE2 
Knockout (N2AKO) and N2AKO following re-expression of wild type NSMCE2 (N2A WT1) and re-expression of ligase 
dead NSMCE2 (N2AR2 and N2AR3) as well as 2mM Hydoxy urea treated cells (16h) from each cell line. Cells are 
strained with propidium iodide to visualise the DNA content. 4000 cells analysed. HydroxyUrea treatment carried 
out for 16h. 
 
Upon analysis, 2mM HU treatment clearly does cause each NSMCE2 cell line to halt 
the cell cycle progression into G2, shown in Fig. 29. As expected, the cell cycle profile 
of the treated MRC5 cells displays a loss of the G2 peak, suggesting that there is an 
accumulation of cells at the G1/S border and in S phase. A similar result was also 
attained in both the N2A KO as well as the N2A KO with wild type NSMCE2 re-
expression. Even in the NSMCE2 ligase-dead cell lines, where most of the population 
was in mid S phase even in the absence of replication stress treatment, it is clear that 
HU treatment has reduced the proportion of cells within the >4N population by 
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preventing re-replication. These data suggest that the NSMCE2 ligase activity of the 
SMC5/6 complex is likely not involved in the activation of the replication checkpoint.  
 
However, in order to confirm this theory further, we analysed Chk1 phosphorylation 
following 2mM HU treatment (16h) of each NSMCE2 cell line. This was undertaken by 
western blot with antibodies against phosphorylated (a-Chk1pS345) and un-
phoshorylated forms of Chk1. The results of this experiment can be seen in Fig. 30.  
 
 
Fig. 30 confirms that each of the NSMCE2 cell lines is able to activate the replication 
checkpoint and phosphorylate Chk1 when treated with HU, including the ligase-dead 
mutants.  These data indicate that the replication checkpoint response is intact in both 
the N2A KO and ligase dead mutant cells. Indeed, the response is even more robust in 
the NSMCE2 ligase-dead mutants. However, at the top of the panel of the 2mM HU 
treated MRC5 cell sample, there is a faint band, possibly indicating another form of 
phosphorylated Chk1 which is present when the checkpoint is fully activated. This is 
also present within the 2mM HU treated N2A R3 cell line sample, but none of the other 
mutant cell lines. It is then possible that although these cell lines seem to be able to 
phosphorylate Chk1 and so activate the replication checkpoint, they may not be able 
to trigger the complete checkpoint response, implying NSMCE2 may be involved in this 
process.  
 
Figure 30 - Western blot showing the expression of phosphor-Chk1, Chk1 and GAPDH in both untreated and 2mM 
Hydroxy Urea (HU) treated (16h) Wild type MRC5, NSMCE2 knockout (N2AKO) as well as NSMCE2 knockout 
following re-expression of wild type NSMCE2 (N2A WT) and re-expression of ligase-dead NSMCE2 (N2A R2 and N2A 
R3) cell lines. GAPDH is used as the loading control. 
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Nonetheless, this data indicates that, although the ligase-dead mutants clearly 
struggle with replication, this replication challenge is either not enough to activate the 
checkpoint (although we question this following the cell cycle and proliferation data), 
or the specific replication challenge caused by mutation of the NSMCE2 ligase is not 
sensed or responded to by the replication checkpoint.  
 
Unexpectedly, there is a decrease in the level of Chk1 expression within the N2A WT 
cell line. This suggests that although the re-expressed wild type NSMCE2 is sufficiently 
expressed and forms the full SMC5/6 complex, it may not be interacting with cellular 
pathways in exactly the same way as the wild type cell line and therefore is not 
producing the same effects. This is important to consider for future studies using these 
cell lines.  
 
3.3 Assessment of the ability of the NSMCE2 cell lines to complete replication 
 
3.3.1 Analysis of the NSMCE2 cell lines ability to activate the decatenation checkpoint  
 
The slow proliferation seen by the NSMCE2 knockout cells as well as the NSMCE2 
ligase-dead cells may be explained by their difficulty moving through S phase, as 
shown in the previous FACS data. We have determined that this is not due to the 
activation of the replication checkpoint although activation of the DNA damage 
checkpoint may contribute to the slowed S phase completion. The fact that the 
NSMCE2 ligase dead cells accumulate significant >4N DNA content suggests that these 
cells also may have a problem completing replication, particularly in efficiently 
segregating their DNA as they grow and divide. Moreover, several other SMC5/6 
studies have implicated the complex in removing connections between chromosomes, 
which is vital to allow correct DNA segregation and cytokinesis (Gallego-Paez et al., 
2014; Bermúdez-López et al., 2010; Torres-Rosell et al., 2007; Torres-Rosell et al., 
2005).   
 
To investigate the ability of the NSMCE2 cell lines to efficiently segregate their DNA, 
NSMCE2 mutant cells were treated with ICRF-193 (10µM) an inhibitor of DNA 
 81 
topoisomerase II (Topo II). This enzyme is required for the separation of a specific type 
of connection between intertwined sister chromatids, catenations. Therefore, 
providing the cells are able to, inhibiting this enzyme should activate the decatenation 
checkpoint, which blocks the cell cycle within G2/M to allow for these chromatid 
connections to be removed, prior to mitosis (Holm, 1994; Charbin et al., 2014). 
However, if they are unable to activate the decatenation checkpoint, then inhibiting 
this process should not largely effect their ability to move through the cell cycle, but 
connections between sister chromatids will not be removed as TopoII is inhibited. To 
investigate this possibility, cell cycle analysis was performed by flow cytometry for 




Figure 31 - Flow cytometry analysis showing the cell cycle proportions of untreated wild type MRC5 cells, NSMCE2 
Knockout (N2AKO) and N2AKO following re-expression of wild type NSMCE2 (N2A WT1) and re-expression of ligase 
dead NSMCE2 (N2AR2 and N2AR3) as well as 10µM ICRF-193 treated cells from each cell line. Cells are strained 
with propidium iodide to visualise the DNA content. 4000 cells analysed. Treatment carried out for 16h. 
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As shown in Fig. 31, it is clear that within the MRC5, NSMCE2 knockout and NSMCE2 
knockout cells with wild type NSMCE2 re-expression, ICRF-193 treatment is able to 
effectively activate the decatenation checkpoint. This suggests that these cell lines all 
have a functional decatenation checkpoint which halts the cells at the G2/M border 
successfully. However, within both the NSMCE2 ligase dead cell lines, following ICRF-
193 treatment, the cells do not accumulate within G2, but instead continue to re-
replicate their genome, producing a >4N population of cells. This suggests that the 
decatenation checkpoint is not operating to prevent missegregation when expressing 
the catalytically inactivated version of NSMCE2, implicating the NSMCE2 ligase activity 
within the activation or maintenance of the decatenation checkpoint and in the proper 
segregation of chromosomes.  
 
3.3.2 Immunofluorescence analysis of the NSMCE2 cell lines 
To further investigate the possibility that NSMCE2 may be involved in chromosome 
segregation, given the accumulation of >4N DNA content and an inability to block at 
the decatenation checkpoint in the NSMCE2 ligase-dead mutants, 
immunofluorescence was used to analyse cell division in each NSMCE2 cell lines. Two 
key parameters were monitored. Firstly, since the ligase-dead mutant cells accumulate 
a >4N DNA content and have problems segregating their DNA, we speculated that cell 
division may be compromised alongside chromosome segregation, and that this may 
result in increased cell size as cells continue to grow but fail to divide. Therefore, we 
measured overall cell size in each NSMCE2 cell line. Secondly, it is currently thought 
that some mutant cells that fail to accurately segregate their DNA, may do so because 
they enter mitosis before replication of the entire genome is complete. These cells 
would enter mitosis with unresolved connections between sister chromatids, such as 
unreplicated regions or collapsed fork intermediates, which then cause difficulty for 
successful DNA segregation. Cells which do this form mitotic DNA structures, such as 
micronuclei and anaphase bridges (Mankouri et al., 2013). Micronuclei are tiny extra-
nuclear bodies of DNA. They are often caused by extensive DNA damage directly due 
to RS or due to defects in chromosome segregation often caused by RS (Fenech and 
Morley, 1985; Mateuca et al., 2006). Micronuclei are frequently noted as a footprint 
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for chromosome missegregation. As the SMC5/6 complex is often associated with RS 
resolution, it is possible that the chromosome segregation deficiency causing the >4N 
population within the ligase-dead cells could be due to an inability of the cells to 
remove replication intermediates characteristic of RS. Therefore, we determined the 
numbers of micronuclei within the NSMCE2 mutant cell lines to give further insight as 
to whether the NSMCE2 ligase activity may be involved in S phase completion before 
entry into mitosis, directly or indirectly.  
 
In order to analyse the NSMCE2 cell lines by immunofluorescence, cells from each cell 
line; wild type MRC5, N2A KO, N2A KO with wild type NSMCE2 re-expression (N2AWt1) 
and N2AKO with NSMCE2 ligase-dead expression (N2AR2 and N2A R3), were grown on 
coverslips, then fixed and stained using method 2.3.4. Individual cells were then 
visualised by staining with a-tubulin antibody, detected using fluorophore 633-
conjugated secondary antibody, while cellular DNA was stained with DAPI. The slides 
were then visualised using a confocal microscope and the average cell sizes and 
quantity of micronuclei present were determined for each cell line.  
 
To investigate cell size, at least 200 cells of each of the NSMCE2 cell lines were 
measured and the result of this examination can be seen in Fig. 32. There is a 
significant increase in cell size between the MRC5 and each of the N2A KO, N2A R2 and 
N2A R3 cell lines (P<0.001). The average (mean) size of the MRC5 cells was 36.9µM 
and this increased to 43.3µM for the NSMCE2 knockout cells and to 51.9µM and 
49.5µM for N2A R2 and N2A R3 respectively. The NSMCE2 knockout cells are therefore 
17% bigger than the MRC5 cells. It is likely that this increase in size is due to continued 
growth throughout the extended cell cycle. However, there is a larger, approximately 
35%, increase in cell size within both ligase-dead NSMCE2 cell lines compared to the 
MRC5 cells. These cells, which proliferate very slowly, were unable to activate the 
decatenation checkpoint and displayed a >4N DNA content under normal growth 
conditions, so it is likely then that these cells are increasing their size alongside an 
increased DNA content, and may have problems completing cell division. Moreover, 
these cell sizes indicate that it is possible the knockout cells are experiencing a mild 
version of the issues faced by the ligase-dead cells, although this is not possible to 
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explicitly determine from this data alone. A representative example of the sizes of each 





















Figure 32 - Box plot to describe the cell sizes of each of the NSMCE2 cell lines; wild type MRC5, NSMCE2 knock 
out (N2A KO), NSMCE2 knockout with re-expression of wild type NSMCE2 (N2AWt1) and NSMCE2 knockout with 
re-expression of ligase-dead NSMCE2 (N2AR2 and N2A R3). Cells were visualised through confocal microscopy 
immunofluorescence using ZEN software and cell size was calculated as the largest measurable linear distance 
across each cell. Cells were mounted using Vectasheild which contained DAPI to stain the DNA. 200 cells analysed 


















As well as studying the size of each of the NSMCE2 cell lines to examine the possibility 
the NMCE2 protein is involved in chromosome segregation, we also analysed the 
number of micronuclei, a product of faulty replication and increased DNA damage, 
produced by each of them. Examples of micronuclei can be seen in Fig 34. At least 200 
cells were analysed for each cell line and the increase in the quantity of micronuclei 
compared to wild type MRC5 control cells is presented in Figure 35.  
 
MRC5 N2A KO N2A WT1 
N2A R2 N2A R3 
Figure 33 - Immunofluorescence pictures taken using a confocal microscope and visualised in ZEN software to 
analyse cell sizes of each of the NSMCE2 cell lines; wild type (MRC5) and NSMCE2 knockout (N2AKO) cells as well as 
N2A KO cells following re-expression of wild type NSMCE2 (N2Awt1) or ligase-dead NSMCE2 (N2AR2, N2AR3). Cells 















Figure 34 - Immunofluorescence pictures taken using a confocal microscope and visualised in ZEN software to 
analyse micronuclei within the NSMCE2 knockout cell line with ligase-dead NSMCE2 restoration (N2A R3). Cells were 























Fig. 35. illustrates that loss of NSMCE2 in its entirety causes a greater than 1.5 fold 
increase in the number of micronuclei found within the cells. As these structures often 
form following RS and DNA segregation difficulties, these data directly associate 
NSMCE2 with either of these processes. Furthermore, loss of only the catalytic 
NSMCE2 subunit causes a much more severe, 3-fold, increase in micronuclei within 
the cell lines compared to control MRC5 cells. As well as the increased micronuclei, 
also note that there was an increase in globular nuclei within the NSMCE2 ligase-dead 
cell lines, such as the one shown in the N2AR3 cell line in Fig. 33. This data strongly 
supports the theory that the ligase-dead NSMCE2 cells are having problems with 
replication and segregation, suggesting that this may be due to RS causing an 
incomplete S phase before mitosis, with the known roles of the SMC5/6 complex in 
DNA damage repair and the RS response hard to ignore. However, it is also entirely 
possible that NSMCE2 may also be directly involved in chromosome decatenation and 
segregation itself, which would again directly cause the increase in micronuclei. This 
data again suggests the possibility that the NSMCE2 knockout cell line may be 
experiencing a mild defect similar to that of the NSMCE2 ligase dead cell lines.  
 
Figure 35 - Fold increase in the number of micronuclei within each of the NSMCE2 cell lines; NSMCE2 knockout 
(N2AKO) cells as well as N2A KO cells following re-expression of wild type NSMCE2 (N2Awt1, N2Awt6) or ligase-
dead NSMCE2 (N2AR2, N2AR3), when compared to the wildtype MRC5 cells. Cells were analysed through confocal 
microscopy immunofluorescence and were mounted using Vectashield which contained DAPI. At least 200 cells were 
analysed per cell line. 
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3.4 Protocol Development for the bioSUMO strategy  
 
The NSMCE2 SUMO ligase activity is clearly important for chromosome maintenance, 
having been associated with DNA repair and RS recovery processes since its discovery, 
and it is thought that this ligase activity may be how the SMC5/6 complex carries out 
many of its functions (Andrews et al., 2005; Chavez et al., 2010; Branzei et al., 2006; 
Kliszczak et al., 2012). For this reason, it is vital that the SUMOylation targets of 
NSMCE2 are identified and the modifications are characterized. These NSMCE2 
knockout and ligase-dead NSMCE2 cell lines provide an opportunity to do so, looking 
for the loss of SUMOylation targets in these mutants relative to the wild type MRC5 
cells. Therefore, we wanted to establish an assay for isolation of SUMOylated proteins 
to apply in these mutant cell lines. To do this, a protocol was adapted from (Pirone et 
al., 2016) and was developed. 
 
In general, the protocol isolates SUMOylated proteins by the action of in vivo 
biotinylation of SUMO molecules before they become conjugated to specific proteins 
within the cell. To do this, cells are transfected with a bio-tagged SUMO conjugate 
expression plasmid, and once the bio-SUMO protein is expressed within cells, it 
becomes rapidly biotinylated through the action of the co-transfected E.coli BirA 
enzyme. These biotin-tagged SUMO molecules are then utilized by the cells 
endogenous SUMOylation system, becoming conjugated to SUMOylation targets 
within the cell. These modified proteins can then be isolated through streptavidin-
based affinity chromatography due to the strong interaction between their biotin-
tagged SUMO modification and streptavidin. Once bound, stringent washes are 
carried out and the SUMO-bound proteins can be eluted before analysis through 
western blotting. A diagram illustrating the overall protocol can be seen in Fig. 36. The 
aim of the following experiments was to optimize this methodology using MRC5 cells 


























3.4.1 Initial investigations of the bioSUMO strategy 
 
Initially, we performed this protocol essentially as described in section 2.2.10, to 
determine whether we could isolate SUMOylated proteins from MRC5 cells, following 
transfection with either bio-tagged SUMO1, SUMO2 or SUMO3, relative to an empty 
vector control. The experiment was undertaken using a 1x10cm plate per transfection 
and the biotin was added into the media 24 hours after the transfection took place. 
The cells were then collected 24 hours after this. The wash procedure took place using 
300µl of each wash buffer in a microcentrifuge tube, which was aspirated for removal. 
Once protein elution from the beads had taken place, 1/10th of the extract, flow 
through and eluate were resolved through SDS PAGE gel electrophoresis before 
western blotting (as methods 2.2.4 and 2.2.5) with Streptavidin HRP antibody in order 
to highlight any biotinylated SUMO-conjugated proteins. The results can be seen in 
Fig. 37.  
Figure 36 - Diagram outlining the method used to detect SUMOylated proteins within human cells. The bio-
SUMO1 conjugate becomes expressed in cells following plasmid transfection. This bio-tagged conjugate becomes 
biotinylated through the action of BirA meaning when a SUMO ligase attaches this SUMO molecule to a target 
protein, the target protein has a biotin tag and can be purified with streptavidin beads. The protein elution from 














Fig. 37 demonstrates that the methodology and pulldown has been successful. This is 
particularly clear within the SUMO-2 and SUMO-3 lanes, as the SUMOylated proteins 
in the extract samples, tagged with either SUMO-2 and SUMO-3 (»50kDa) have been 
concentrated in the eluates of these samples. There is no obvious pull down of an 
individual SUMOylated protein tagged with SUMO-1 from the extract to eluate, 
however, there is a smear of SUMOylated proteins found in all three of the SUMO 
eluates from 100kDa upwards as well as a band at ~85kDa in each lane, that were not 
detected in eluate in the absence of SUMO expression. This ~85kDa band signifies a 
protein tagged with either SUMO-1, SUMO-2 or SUMO-3 respectively, that has been 
concentrated from the extract to the eluate using this protocol. It is not possible to 
visualise free SUMO in this experiment as it has run off the bottom of the gel.  As this 
was only 1/10th of the eluate, the sensitivity was quite high and we assumed that we 
could achieve much higher yields, enabling the isolation of specific SUMOylated 
proteins, with the remaining eluate.  To achieve this, the remaining sample was 
resolved through SDS-PAGE gel electrophoresis before western blotting. The NSMCE2 
component of the SMC5/6 complex is auto-SUMOylated in vivo (Potts and Yu, 2005), 
so this was a good candidate for analysis, to determine the possibility of detecting 
Figure 37 - Western Blot showing SUMOylated proteins isolated from MRC5 cells following transfection with pbio-
V (empty vector control), pbio-SUMO-1. pbio-SUMO-2 and pbio-SUMO3. The blot was probed with Streptavidin 
HRP to visualise all SUMOylated proteins due to their biotin tag. Samples equivalent to 1/10th volume of eluate and 
of cell extract from one 10cm plates per transfection is shown.  
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specific SUMOylated proteins within the eluate. The result of this western blot, probed 




Figure 38 - Western Blot showing SUMOylated proteins isolated from MRC5 cells following transfection with pbio-
V (empty vector control),, pbio-SUMO-1. pbio-SUMO-2 and pbio-SUMO3. The blot was probed with NSMCE2 
antibody to visualise unmodified and SUMOylated NSMCE2 proteins. Samples equivalent to 9/10th volume of eluate 
and cell extract from one 10cm plates per transfection is shown. Xt - extract, FT- flow through, El - Eluate. 
 
As shown in Fig. 38, the NSMCE2 antibody cross-reacts with multiple bands in each of 
the eluate fractions, including the negative control (vector) eluate. This suggests that 
these relate to non-specific protein interactions with the streptavidin beads. 
Therefore, to reduce the level of non-specific binding, the experiment was repeated 
using more stringent wash conditions. These washes took place in a spin column to 
remove all traces of each wash buffer, with vigorous inversions to ensure thorough 
washing. An increased volume of 500µl of each wash buffer was also used for each 
wash. This experiment used only the SUMO-1 and Vector only plasmids transfected 
into wild type MRC5 cells, as well as MRC5 controls with and without biotin 
supplementation. The timings for transfection and biotin supplementation were the 
same as the previous experiment. The results of this western blot when probed with 




Fig 39A illustrates that after more effective washing, a much cleaner eluate is 
achievable, with some SUMOylated proteins highlighted within the SUMO-1 eluate 
fraction which are not present within the controls. Although this is a positive result, 
the detection level is relatively low, and we were unable to detect any SUMOylated 
NSMCE2 in the SUMO1 eluate in this experiment (see Fig 39B). Given the low level of 
total SUMOylated protein detected in this experiment it seems likely that any 
SUMOylated NSMCE2 may be below the level of detection in this experiment. 
Consequently, the experiment was then repeated for bio-SUMO-1 and an empty 
vector control, using the same conditions but scaling up the quantity of material used 








Figure 39 - Western Blot showing SUMOylated proteins isolated from MRC5 cells following transfection with pbio-V 
(empty vector control) and pbio-SUMO-1. Un-transfected wild type MRC5 cells were also analysed both with and 
without Biotin addition. The blot was probed with Streptavidin HRP (A,) which detects all biotinylated proteins to 
allow us to visualise SUMOylated proteins, and NSMCE2 antibody (B) to visualise unmodified and SUMOylated 
NSMCE2 proteins. Samples equivalent to ½ volume of eluate and ½ volume of cell extract from one 10cm plates per 

















Fig. 40 demonstrates that with four times as much cell material, it was possible to 
effectively isolate SUMOylated NSMCE2 using the bioSUMO method. The dark band 
within the SUMO-1 eluate at » 40 kDa is expected to be mono-SUMOylated NSMCE2 
whilst the large smear above this likely representing poly-SUMOylated forms. In 
contrast, no NSMCE2 cross-reacting bands are detected in the vector only eluate 
sample, confirming the specificity of the isolate procedure.  
 
Unfortunately, although this result was very promising, we were unable to reproduce 
this result in further attempts. Therefore, in order to confirm the reliability of the 
methodology we were using, we began to validate every stage to ensure it was 




Figure 40 - Western Blot showing SUMOylated proteins isolated from MRC5 cells following transfection with 
pbio-V (empty vector control),  and pbio-SUMO-1. The blot was probed with NSMCE2 antibody to visualise 
unmodified and SUMOylated NSMCE2 proteins. Samples equivalent to 4/5th volume of eluate and ½ volume 





3.4.2 bioSUMO methodology validation 
 
The first thing we checked was the transfection efficiency. The experiment was 
undertaken using MRC5 cells transfected with a plasmid containing a GFP sequence to 
determine the expression levels of GFP at different ratios of transfection reagent to 
DNA. The ratios of reagent to DNA were 2:1, 3:1 and 4:1 along with an untransfected 
control and transfection efficiency was calculated on the basis of GFP expression. The 
results are shown in Table 6.  
 
Table 6 - Table to show transfection efficiency of Wild type MRC5 cells when transfected with a plasmid containing 
GFP at transfection ratios of 2:1, 3:1 and 4:1 and untransfected. Cells were grown in Antibiotic free media to reach 
90% confluency before transfection and collection after 24h. Cells in PBS were directly visualised by Flow 
cytometry using BD Canto II in PBS. 








Table 6 shows that the transfection efficiency at each of the tested ratios is above 50%. 
This would be high enough to visualise the results we were expecting and we were 
using a ratio of 3:1 so it was ruled out as a reason for the experiment not working.  
 
To limit the variability problems due to the inconsistency we had seen using the 
Streptavidin HRP antibody, we decided to use an alternative anti-biotin HRP antibody 
which should reliably detect all proteins with a biotin tag. In order to use this antibody, 
the detection capabilities of the antibody were first tested. A range of concentrations 
of Biotin-tagged SUMO were resolved by SDS-PAGE and western blotted using anti-









Figure 41 - Western Blot demonstrating the ability of the Anti-Biotin HRP antibody to detect concentrations of Bio-
tagged SUMO. 
Fig. 41 confirms that the Anti-Biotin HRP antibody can detect biotin-tagged SUMO 
protein at as little as 0.02µg.  
 
The biotin-streptavidin interaction is known to be extremely strong and so we 
considered the possibility that one difficulty in detecting SUMOylated proteins, 
following our isolation procedure, may be related to the difficulty in fully eluting the 
biotinylated SUMO-tagged proteins from the streptavidin beads (Rybak et al., 2004). 
Therefore, to determine if a more effective removal method could be found, 1.5µg of 
recombinant biotin-SUMO1 was bound to 60µl of streptavidin beads overnight in a 3:1 
ratio of bind and lysis buffer as described in the original protocol. The beads were then 
split three ways and three different elution methods were tested for biotin-tagged 
SUMO1 elution. The first method was as described within the methods section and as 
used for all previous experimentation, with the addition of 4x loading buffer and 
200mM DTT along with heat and agitation, the second involved boiling the beads in 
2% SDS, 10mM Biotin and 6M Urea and the third involved boiling the beads in 10mM 
EDTA and 10mM Biotin in 95% Formamide (Rybak et al., 2004). In addition, in order to 
maximise protein loading, samples were acetone precipitated and resuspended in a 
minimal volume prior to SDS-PAGE gel electrophoresis and western blotting (see 










Figure 42 - Western blot to compare efficiency of elution methods for removal of biotinylated proteins from 
Strepatavidin beads using three different elution methods; 1- 30µl SUMO Elution buffer added, 99°C for 8 minutes, 
brief vortex and 99°C for 5 minutes, 2- 24µl 2% SDS, 10mM Biotin, 8M Urea in PBS added and incubated for 15 
minutes at RT, 96°C for a further 15 minutes following the addition of 6µl 5x SDS PAGE loading buffer, 3- 15µl 10mM 
EDTA, 10mM biotin in 95% Formamide added and incubated for 5min at 90°C before 15µl 2x loading buffer was 
added. Recombinant bio-SUMO protein = 0.5. Input sample = 0.5µg bioSUMO following acetone precipitation to 
concentrate. Each set of beads for elution had 0.5µg of Bio-SUMO protein bound to 20µl beads O/N. The flow 
through underwent acetone precipitation before loading.  
As shown in Fig. 42, the first elution method, which we had used in previous 
experiments, was the most effective at removing the bio-SUMO protein from the 
Strepatividin beads, with the eluate having very similar intensity to the input sample 
suggesting a very good level of recovery of biotin-SUMO1. This implies that it is not 
the removal of the proteins from the beads which is preventing detection of 
SUMOylated proteins in our experimental isolates. At this point, each stage of the 
protocol had been successfully validated so it was difficult to determine what was 




Following the quality control tests to assess the ability of the bioSUMO method to 
isolate SUMOylated proteins from cell extract, the experiment was repeated with 
MRC5 cells transfected with SUMO-1 as the experimental sample and untransfected 
wild type MRC5 cells as the negative control. Two 10cm plates were used for each 
condition and the methodology described in method 2.2.10, with the more stringent 
washes, was scaled up appropriately, apart from the concentration of NEM which was 
doubled to ensure the maintenance of SUMOylated proteins. Biotin was included in 
the growth medium from the point of transfection and the cells were collected 32 
hours later. Following this, half of the extract, flow through, and eluate from each 
condition were resolved through SDS PAGE gel electrophoresis before western 
blotting (see method 2.2.4 and 2.2.5) and the membrane probed with anti-biotin 





Figure 43 - Western Blot showing SUMOylated proteins isolated from MRC5 cells following transfection with pbio-V 
(empty vector control) and pbio-SUMO-1. The blot was probed with anti-biotin HRP to visualise all SUMOylated 




As shown in Fig. 43, using this method it was clearly possible to isolate SUMOylated 
proteins from SUMO-1 transfected wild type MRC5 cells (free bio-SUMO1 and SUMO-
1 protein conjugates) as shown by the large smear of proteins within the S1 eluate 
which is not present within the control samples. The other half of these experimental 
samples were western blotted with anti-RanGAP1 antibody to detect SUMOylated 
RanGAP1, a relatively abundant SUMOylated protein (Matunis et al., 1996). This 
enabled determination of the sensitivity of the experimental protocol. The result of 
this western blot is shown in Fig. 44.  
 
 
Figure 44 - Western Blot showing SUMOylated proteins isolated from MRC5 cells following transfection with pbio-
V (empty vector control) and pbio-SUMO-1. The blot was probed with anti-RanGAP antibody to visualise unmodified 
and SUMOylated RanGAP proteins. Samples equivalent to ½ volume of eluate and of cell extract from two 10cm 
plates per transfection is shown. 
 
Fig. 44 illustrates that using these conditions only a small amount of SUMOylated 
RanGAP was isolated, possibly giving an explanation as to why we were unable to see 
any SUMOylated NSMCE2 within many of the previous experiments as SUMOylated 
NSMCE2 is likely to be much less abundant than SUMOylated RanGAP. To overcome 
this, the experiment was repeated once more using more plates per sample but again 
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no SUMOylated NSMCE2 could be detected. Due to the time constraints of this 






















Chapter 4: Discussion  
 
RS and GI play a key role in driving the development and progression of cancer. RS is 
defined as replication challenges such as physical blocks which cause the slowing, 
stalling or collapsing of replication forks (Zeman and Cimprich, 2014). This stress 
causes the activation of the S phase checkpoints, which allows the DDR to be carried 
out to repair any damage caused, as well as allowing the replication fork to reform 
once the source of the stress has been resolved (Mazouzi et al., 2014). These 
mechanisms act as a surveillance system with the aim of preserving genome integrity 
and preventing genetic changes. However, where RS occurs more frequently, such as 
at common fragile sites, chromosomes are prone to rearrangements during repair of 
collapsed forks. This can lead to mutations and loss of heterozygosity, inducing a state 
of GI, which can drive the development of cancer (Halazonetis et al., 2008; Beckman 
and Loeb, 2006). In precancerous lesions, where a mutation has occurred in an 
oncogene causing dysregulated proliferation, increased RS and GI causes the 
activation of p53 which acts as a tumourigenesis barrier. However, ongoing RS and GI 
provides a continual pressure for p53 mutation, which would lead to the evasion of 
cell death and so the development of cancer (Halazonetis et al., 2008).  
 
Due to this possible chain of events, it is clearly important that the repair and recovery 
from RS and its consequences are highly effective. A key molecule known to be 
involved in this process is the SMC5/6 complex (Lehmann et al., 1995). This protein 
complex is a member of the structural maintenance of chromosomes family, along 
with cohesin and condensin, and is made up of 6 key components; SMC5, SMC6, 
NSMCE1, NSMCE2, NSMCE3 and NSMCE4 (Taylor et al., 2001; Taylor et al., 2008; 
Harvey et al., 2004; Potts and Yu, 2005).  The NMSCE2 component is a vital protein 
with SUMO ligase capabilities, debated to be the means by which the SMC5/6 complex 
carries out the majority of its functions (Andrews et al., 2005; Rai et al., 2011).  
 
Since its discovery, the SMC5/6 complex was linked to genome maintenance and 
repair of DNA damage (Nasim and Smith, 1975; Lehmann et al., 1995). Originally, there 
was strong evidence from epistasis analysis that the yeast SMC5/6 complex was 
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involved in the repair of damage through HR, with the complex being directly 
associated with the RAD51 pathway (McDonald et al., 2003; Lehmann et al., 1995). 
This was later supported in many cell types including human cells where the 
inactivation of SMC5/6 caused defects in HR (Potts and Yu, 2007). Furthermore, 
research suggests that the SMC5/6 complex may act to remove recombination 
intermediates formed by stalled or collapsed forks through HR mechanisms 
(Ampatzidou et al., 2006; Branzei et al., 2006), possibly with the help of cohesin (Kegel 
and Sjögren, 2010). 
 
As well HR, there are many other possible roles for the SMC5/6 complex. For example, 
the complex has been seen to prevent accumulation of positive supercoiling ahead of 
the replication machinery to minimize stress as well as remove protein connections 
between sister chromatids to allow for efficient segregation (Kegel et al., 2011; Outwin 
et al., 2009). Moreover, two human patient studies have identified that destabilization 
of the entire SMC5/6 complex or the loss of only NSMCE2, causes the formation of 
mitotic DNA structures such as micronuclei and nucleoplasmic bridges, often formed 
as the result of hindered chromosome segregation, as well as increased DNA damage 
at a cellular level. The NSMCE2 mutant patients also present with primordial dwarfism, 
a clinical feature often associated with DNA damage disorders (Payne et al., 2014; van 
der Crabben et al., 2016). Due to the wide range of possible genome maintenance 
functions suggested for the SMC5/6 complex, it has been postulated that the role of 
the complex may be to coordinate many of these processes.  
 
As there is a question mark over the current role of NSMCE2, its SUMO ligase function 
and the SMC5/6 complex as a whole, the aim of this study was to characterize human 
NSMCE2 CRISPR-Cas9 cell lines which had been produced by this laboratory (NSMCE2 
knock out, NSMCE2 knockout with wildtype NSMCE2 re-expression and NSMCE2 
knockout cells with ligase-dead NSMCE2 expression) in order to determine a possible 




4.1 Confirmation of the NSMCE2 cell lines 
 
Throughout the study of the SMC5/6 complex, many different cell types have been 
used and different methods to remove the function of part or all of the complex have 
been demonstrated. Initially much of the early work was undertaken using budding 
and fission yeast, however there was a difference in structure and requirement for the 
Nse5 and Nse6 subunits between the two yeast strains suggesting that the functions 
and interactions may be variable between species (Pebernard et al., 2006; Duan et al., 
2009) (Stephan et al., 2011b). When the SMC5/6 complex was later isolated in humans 
it was found to have a very similar structure to the fission yeast (Taylor et al., 2008; 
Verver et al., 2016a), however SLF1 and SLF2 (the Nse5 and Nse6 equivalents) were 
not part of the core complex and showed little homology (Räschle et al., 2015). At this 
time there were also discrepancies between the results of the yeast and human cells. 
For this reason, it was important to this project that the cell lines we used were human, 
allowing us to make valid conclusions as to the function of the SMC5/6 complex within 
human chromosome maintenance and repair.  
 
Previous studies of the human SMC5/6 complex have mainly used RNAi knockdowns 
of part or all of the complex to try and determine function (Gallego-Paez et al., 2014; 
Potts et al., 2006; Potts and Yu, 2005; Taylor et al., 2008). However, the use of these 
techniques often still allows the gene to be partly expressed despite the knockdown, 
therefore making clear conclusions challenging as the protein is still partly able to 
function. There is also a risk of large scale off target effects, some of which have been 
documented within SMC5/6 RNAi knockdown studies (Wu et al., 2012). For these 
reasons, the more effective method of CRISPR-Cas9 genome editing was used to 
manufacture the stable NSMCE2 mutant cell lines used in this project. The project also 
utilised NSMCE2 knockout cell lines in which wild type NSMCE2 expression was 
restored. This allowed confirmation that any effects seen within the mutant cells were 
specific to the loss of NSMCE2 or its ligase capabilities, not from off target effects, 
providing more valid conclusions to be drawn and greater insight into NSMCE2 and its 
possible roles (Boettcher and McManus, 2015).  
 
 103 
To validate these NSMCE2 mutant cell lines, western blotting confirmed that NSMCE2 
expression had been completely abolished within the NSMCE2 knockout cell line and 
restored in the NSMCE2 wild type and ligase-dead re-expression cell lines, albeit 
slightly over-expressed. There was no effect on the other component expression, as 
expected, further confirming the validity of the CRISPR-Cas9 knockout expression. 
Following this, it was important to identify the effect the removal of NSMCE2 or its 
SUMO ligase expression had on the ability of the whole complex to assemble. It was 
expected that the rest of the complex would be able to form as NSMCE2 does not sit 
as part of the main complex, only bound to SMC5, and the immunoprecipitation assay 
confirmed this (Duan et al., 2009; Andrews et al., 2005; Sergeant et al., 2005). This 
allowed us to draw conclusions about the specific loss of the NSMCE2 subunit or its 
SUMO ligase activity, rather than the loss of the entire complex. It was also important 
to note that the re-expressed NSMCE2, with and without the SUMO ligase function, 
assembled into the SMC5/6 complex, determining that not only is it expressed, but it 
is interacting with the complex components as normal. The information gained from 
these experiments gave us the insight to confidently use each of the NSMCE2 cell lines 
for further analysis, providing us the ability to determine how NSMCE2 is involved in 
DNA maintenance and repair in human cells.  
 
4.2 Cell Cycle analysis for each of the NSMCE2 mutant cell lines 
 
Previous to this study, proliferation data had been collected for each of the NSMCE2 
cell lines described, indicating that the NSMCE2 knockout cell line had a mild 
proliferation defect whilst the NSMCE2 ligase dead cell lines had a very severe 
proliferation defect, proliferating at approximately half the rate of MRC5 cells. This is 
supported by a previous study of CRISPR-Cas9 NSMCE2 knockout human cells which 
demonstrated slowed proliferation, although this study could not verify that all effects 
seen were solely dependent upon NSMCE2 knockout (Verver et al., 2016b). However, 
it was not clear why the defects seen within our NSMCE2 mutant cells were occurring, 
whether the slow proliferating cell lines were having issues progressing through a 
specific cell cycle phase, through the entire cell cycle or whether they were 
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experiencing large-scale cell death. For this reason, it was vital that cell cycle analysis 
by FACS was undertaken on each mutant cell line.  
 
Early studies in budding yeast demonstrated that the undefined role of the SMC5/6 
complex may be occurring in S phase (Torres-Rosell et al., 2007), with many other 
studies later describing more specific S phase progression roles. These include; DNA 
damage repair, recovery from collapsed replication forks by HR, regulating efficient 
overall segregation and correct chromosome structure when moving from replication 
into mitosis, and managing replication fork pausing sites particularly in rDNA 
replication (Ampatzidou et al., 2006; Gallego-Paez et al., 2014; Peng et al., 2018; 
McDonald et al., 2003; Menolfi et al., 2015). Furthermore, previous FACS analysis 
undertaken on SMC5/SMC6 siRNA treated human cell lines have revealed a delay and 
slowed progression through S phase, further supporting an S phase role for the 
SMC5/6 complex (Gallego-Paez et al., 2014). As it is widely suggested that NSMCE2 
carries out many of the SMC5/6 functions, we anticipated that both the NSMCE2 
knockout and the NSMCE2 ligase-dead cell lines would follow this trend and both 
demonstrate cell cycle stage specific S phase defects under FACS analysis.  
 
The FACS profile analysis of the NSMCE2 knockout cells confirmed that the 
proliferation defect was due to a mild cell cycle stage specific defect, with an increased 
proportion of cells found within S and G2 phases, as expected. Moreover, both 
NSMCE2 ligase-dead cell lines had a very large increase in S phase cells, with almost 
no cells found within G1. Surprisingly, these cell lines also presented a >4N population 
of cells with a second S phase peak within a second cell cycle. This 8N content indicates 
that the ligase-dead cells may be undergoing ‘re-replication’ rather than segregating 
their DNA content and undergoing cytokinesis. This is supported as chromosome 
segregation has been suggested as a key function of the SMC5/6 complex (Gallego-
Paez et al., 2014; Bermúdez-López et al., 2010; Torres-Rosell et al., 2007; Torres-Rosell 
et al., 2005).   
 
Following the S phase replication roles already suggested for the SMC5/6 complex, we 
hypothesised that the slow S phase progression noted in both the NSMCE2 knockout 
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and NSMCE2 ligase-dead cells possibly occurs due to problems incurred during 
replication or difficulty recovering from RS. This slowed replication could cause 
unreplicated regions and unresolved RS intermediates to persist which would then 
lead to the segregation defects thought to be occurring within the NSMCE2 ligase dead 
cells. As there is thought to be no segregation defects within the NSMCE2 knockout 
cell line, it is possible that the slowed S phase progression is not as severe as the ligase-
dead cells, meaning that replication can be completed in time leaving no unresolved 
issues. Likewise, it is also possible that the NSMCE2 knockout cell line is just as slow at 
replication, but the unreplicated regions and RS intermediates left behind are able to 
be resolved unlike within the ligase-dead cell line. We thought that expression of the 
catalytically inactivated version of NSMCE2 may be the result of a dominant-negative 
mutation, therefore allowing the latter effect to take place. The ligase-dead NSMCE2 
may be acting to disrupt functions carried out by other components of the SMC5/6 
complex or other factors which act in substitute following the absence of NSMCE2, 
such as other SUMO ligases or resolvase enzymes. These factors may be unable to be 
recruited to the sites where they are required as non-functional NSMCE2 is present 
and so is blocking their action. This has been suggested in a previous study which 
demonstrated that catalytically inactivated yeast NSMCE2 mutant cells had increased 
occupancy at DNA damage sites when compared to wild type cells, blocking the action 
of other proteins (Tapia-Alveal and O'Connell, 2011). As well as replication 
complications alone possibly causing the slowed S phase progression seen both 
following the loss of the entire NSMCE2 subunit or just its catalytic activity, it is 
possible that activation of the DNA damage or S phase replication checkpoints may be 
also contributing to this effect.  
 
The subtle difference in S phase progression as seen between the NSMCE2 knockout 
and control cells can only be broadly visualised by this FACS presentation of the data. 
It would be important to follow this data up by pulse labelling populations of these cell 
lines with 5-ethynyl-2’-deoxyuridine (EdU) in order to determine the quantity of cells 
in S phase and the specific lengths of time they spend in this phase per cell cycle 
(Pereira et al., 2017). This would allow more specific accurate quantification of the 
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differences between the FACS profiles and so allow more precise conclusions to be 
drawn.  
 
Throughout the study of the NSMCE2 mutant cell lines it became clear that the cells 
were prone to reversion, altering their proliferation rates and FACS profiles, 
particularly the ligase-dead cell lines. It is possible that the NSMCE2 ligase-dead cell 
lines began suppressing the expression of the ligase-dead NSMCE2 as we have noted 
that the cells seem to progress through the cell cycle better when not expressing 
NSMCE2 at all. It may also be possible that both the knockout and ligase-dead NSMCE2 
cell lines begin to upregulate other cellular SUMOylators which may partially 
compensate for the loss of the NSMCE2 capabilities, or may upregulate the expression 
of other proteins which may undertake a similar genome maintenance role as 
NSMCE2. This meant that all the data had to be carefully studied and repeated in order 
to draw valid conclusions. All the NSMCE2 mutant cell data presented within this thesis 
was acquired reproducibly and all questionable data has been omitted but this should 
be considered within all future analysis of these cell lines.  
 
4.3 Activation of the S phase checkpoints 
 
Throughout its study, the SMC5/6 complex has frequently been associated with 
genome maintenance, specifically DNA repair and RS tolerance. The complex was 
connected with DNA repair following initial yeast studies where SMC5/6 knockout cells 
were very sensitive to damage treatment (Lehmann et al., 1995). Subsequently, many 
studies have been undertaken analysing its repair role, indicating that the SMC5/6 
functions in HR repair with RAD51 in both yeast and human cells, repairing both 
endogenous and exogenously caused DNA damage (Ampatzidou et al., 2006; Potts et 
al., 2006; Verkade et al., 1999; De Piccoli et al., 2006; Harvey et al., 2004). 
Furthermore, its role in recovery from RS was initially shown in S. pombe where it was 
indicated that the complex was vital for the resolution of intermediate structures 
formed following collapsed forks (Ampatzidou et al., 2006). Following this, roles for 
the SMC5/6 complex in early as well as late stage RS recovery were then determined. 
The early stage function involves the stabilisation of the replication fork once it has 
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stalled to avoid collapse, whilst the late stage function involves the resolution of the 
collapsed fork and other intermediates by HR to allow fork restart (Irmisch et al., 2009; 
Branzei et al., 2006; Chen et al., 2013; Bustard et al., 2012). As well as following RS, 
the SMC5/6 complex has also been associated with controlling normal replication. For 
example, the complex is thought to be involved in controlling the organisation of DNA 
replication processing and timing through regulating Topo IIa and condensin binding, 
influencing supercoiling ahead of the replication fork, and regulating fork pausing in 
rDNA as well as elsewhere (Gallego-Paez et al., 2014; Peng et al., 2018; Menolfi et al., 
2015; Kegel et al., 2011).  
 
Due to the suggested functions in DNA repair and RS recovery, it was considered that 
the delayed S phase progression in the NSMCE2 mutant cell lines, may have been, at 
least in part, due to the activation of either of the S phase checkpoints; the DNA 
damage checkpoint or the replication checkpoint in the absence of NSMCE2 function. 
These S phase checkpoints are vitally important for ensuring genetic damage and RS 
are removed, before the cells undergo mitosis and begin the segregation of 
chromatids into two new daughter cells. Both of these checkpoints are able to halt the 
progression of cells through S phase, by the activation of ATM and Chk2 or ATR and 
Chk1 respectively, and so cause the build up of S phase cells found in both the NSMCE2 
knockout and ligase-dead cell lines (Maréchal and Zou, 2013). As well as suggested 
functions following S phase checkpoint activation to resolve any issues faced, the 
SMC5/6 complex has also been associated with maintenance of these checkpoints. For 
example, in yeast, it has been suggested that the SMC5/6 complex is required to 
maintain the S phase DNA damage checkpoint. Mutants were found to activate the 
checkpoint but then continue to carry out aberrant mitosis as DNA repair was not 
undertaken, suggesting the checkpoint was not maintained (Verkade et al., 1999; 
Harvey et al., 2004).  
 
Of course, for DNA damage checkpoint functions to be the cause of the change in cell 
cycle progression, DNA damage must be occurring. Our experiments showed that the 
accumulation of the damage markers, phopho-p53 and g-H2AX, were increased in only 
the NSMCE2 ligase-dead mutants. This implies that only the ligase-dead cells are 
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accumulating DNA damage whilst the NSMCE2 knockouts are not. This is supported by 
the activation state of the S phase DNA damage checkpoint, where the checkpoint is 
only activated within the NSMCE2 ligase-dead cell lines. These results suggest that the 
activation of the DNA damage checkpoint is probably not the cause of slowed S phase 
progression in the knockout cell lines, although it may be at least contributing to this 
phenotype in the ligase-dead mutants.  
 
The increase in DNA damage within the NSMCE2 ligase-dead cells is not unexpected, 
due to the DNA repair and homologous recombination functions of the SMC5/6 
complex described earlier. However, it is surprising that this is not also the case in the 
knockout cell line. As previously described, this could be due the expression of the 
catalytically inactivated version of NSMCE2 being the result of a dominant-negative 
mutation, and so disturbing the action of other proteins which would replace the 
function of NSMCE2 in its absence. This could explain why no DNA damage is noted 
within the NSMCE2 knockout cell lines as other proteins are able to compensate for 
its loss.  
 
Unlike the S phase DNA damage checkpoint, unexpectedly there was no activation of 
the replication checkpoint in any of the NSMCE2 CRISPR-Cas9 mutant cells, with no 
Chk1 activation being noted by western blot by any of the cells. This indicates that the 
S phase replication checkpoint is not causing the delayed S phase progression within 
any of the mutant cell lines. This led us to question whether the obvious replication 
problems the cells were facing, as shown by proliferation assay and FACS analysis, 
were problems which were not sensed by the replication checkpoint or whether the 
SMC5/6 complex and NSMCE2 itself are required for activating the checkpoint. To test 
this, FACS analysis as well as western blotting were undertaken for each of the 
NSMCE2 cell lines following 16 hour 2mM Hydroxyurea (HU) treatment which should 
cause RS and activate the replication checkpoint if it were possible to do so. Both 
methods implied that each of the NSMCE2 cell lines could activate the replication 
checkpoint so it is more likely then that the cause of the slowed S phase progression 
seen by these cells cannot be sensed by the replication checkpoint, or the activation 
of the checkpoint was below the detection level of our protocol. 
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On the basis of what is already known about the RS response functions of the SMC5/6 
complex, it is thought more likely that the replication issues faced by these cell lines 
were directly causing the slowed S phase progression themselves but cannot be 
sensed or responded to by the replication checkpoint. This suggestion is similar to a 
study in S. pombe where Smc6 mutants accumulated RS intermediates as the late 
stage function of the SMC5/6 complex could not prevent fork collapse. These 
intermediates were not recognised by the G2 DNA damage checkpoint, so it is possible 
then that this type of RS may also not activate the replication checkpoint either 
(Ampatzidou et al., 2006). This indicates further interaction between the difficulty 
recovering from RS and DNA damage formation within these NSMCE2 mutant cell 
lines, as well as the fact that genetic damage often causes the RS itself. It is suspected 
that the initial problem, which may be the main cause of the slowed S phase faced by 
these mutant cell lines, is within the RS tolerance/repair pathways, as both the 
suggested SMC5/6 early and late stage functions cannot be carried out so replication 
forks cannot continue when faced with replication challenges. Due to this, 
unrecognised by the replication checkpoint, DNA damage accumulates as the 
replication forks collapse and form RS intermediates. This then causes the activation 
of the DNA damage response pathway, where the damage would normally be repaired 
in an SMC5/6 dependent manner. However, within the NSMCE2 knockout cells it is 
possible that other cellular proteins compensate for the loss of NSMCE2 and remove 
the DNA damage and repair the collapsed replication forks in its place, causing no 
substantial accumulation of DNA damage and activation of the S phase DNA damage 
checkpoint. As discussed earlier, due to the possible dominant-negative mutation, this 
may not occur within the NSMCE2 ligase-dead mutants and so the DNA damage 
remains and the DNA damage checkpoint is activated. It is possible the increased DNA 
damage itself aids the slowed S phase progression by causing more RS within the 
NSMCE2 ligase-dead cells compared to the NSMCE2 knockout cells. However, it is also 
likely that the S phase DNA damage checkpoint may be an additional stimulus.  
 
To determine if activation of the DNA damage checkpoint does aid, at least in part, the 
slow S phase progression within the NSMCE2 ligase-dead cells, it would be important 
to carry out a treatment of ATM inhibitors (ATMi) to each cell line before cell cycle 
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analysis. As ATMi would inhibit the activation of the DNA damage checkpoint, if the 
cells were being halted at this checkpoint, the cell cycle profile would alter to be more 
similar to the NSMCE2 knockout cell lines. However, I believe it is more likely that it is 
the increased DNA damage and unresolved RS itself which is contributing to the 
increased slowing in S phase within the ligase-dead cells compared to the NSMCE2 
knock out cells, with the checkpoint possibly marginally having an influence upon the 
cell cycle. In order to further corroborate the theories postulated within this thesis, it 
would also be necessary to investigate the replication profile, such as speed, fork 
stalling and fork recovery, of each the NSMCE2 mutant cell lines. This would be 
possible through DNA combing (Bianco et al., 2012). I suggest there would be a larger 
amount of stalled forks accumulated as well as reduced recovery within the NSMCE2 
ligase dead cell lines compared to the knockout as the knockout is able to recover 
through other undisturbed cellular pathways. It would also be interesting to determine 
the ability of each NSMCE2 mutant cell line to recover from RS, such as through a mild 
hydroxyurea treatment followed by FACS analysis after different periods of recovery 
time, to establish if the ligase-dead cell lines do in fact struggle to recover from RS 
more than the NSMCE2 knockout cells.  
 
4.4 Segregation of duplicated DNA 
 
The mechanism for chromosome segregation is a complex process, but put simply, 
involves the removal of connections between the sister chromatids and the physical 
movement of the replicated chromosomes to the poles of the mitotic cell, before 
cytokinesis can occur forming two new daughter cells. During cytokinesis, a furrow 
forms down the centre of the newly replicated cell, contracting through the action of 
an actin and myosin band, until a membrane forms separating the two sets of DNA. 
Following this, an abscission step occurs where the two cells can detach from each 
other (Damelin and Bestor, 2007; Guertin et al., 2002).  
 
The process of removing connections between the sister chromatids is vital to avoid 
chromosome breakages and imbalances during chromosome segregation. There are 
two main types of connections found between sister chromatids which need to be 
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resolved; protein cohesin connections and DNA mediated linkages such as catenations 
and other connections such as ongoing replication and unresolved RS characteristics 
(Bermúdez-López et al., 2010). Cohesin physically tethers the two chromatids together 
and removal first occurs throughout the arms of the paired chromatids, in a Wap-1 
dependent manner, before the removal occurs at the centromeric/pericentromeric 
regions independently of Wap-1 (Leman and Noguchi, 2014). Additionally, 
catenations, which interlock the DNA through chain links as sister chromatids pair up, 
are thought to be mainly be removed through the action of TopoII and condensin at a 
checkpoint known as the decatenation checkpoint (Charbin et al., 2014; Holm, 1994). 
Cells can continue to carry out inappropriate cell division in the presence of 
catenations so this checkpoint is essential for ensuring genome stability (Damelin and 
Bestor, 2007). As well as these specific connections, sister chromatids can be 
connected through chromosome junctions; collapsed forks, RS intermediates and 
unexpected ongoing DNA replication. These connections are frequently seen where 
DNA damage is unable to be repaired or in replication mutants (Bermúdez-López et 
al., 2010) 
 
The SMC5/6 complex has been associated with removal of each type of physical 
connection between sister chromatids to allow segregation. It has been suggested in 
S. cerevisiae that the complex controls the distribution and action of Topo II as well as 
condensin within mitosis, indicating a role within decatenation (Gallego-Paez et al., 
2014; Pryzhkova and Jordan, 2016). As well as this, the SMC5/6 complex has a similar 
binding pattern to cohesin throughout mitosis and some SMC5/6 mutants 
demonstrate incomplete mitosis due to cohesin connections still being present 
(Gallego-Paez et al., 2014; Outwin et al., 2009). More recently, it has been indicated in 
S. cerevisiae that the SMC5/6 complex may be more closely involved in the removal of 
DNA mediated linkages between sister chromatids produced due to incomplete 
replication and unresolved RS structures (Bermúdez-López et al., 2010). This was 
corroborated by Branzei et al., 2006 and Farmer et al., 2011 who showed that SMC5/6 
mutant cells undergo inappropriate cell division as these connections are not 
removed. As there is a lack of clarity for the role SMC5/6 plays in the removal of 
connections between sister chromatids and DNA segregation as well as the possibility 
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there is species specific differences, it is important we characterize the capabilities of 
our human NSMCE2 mutant cell lines to complete replication, particularly considering 
the >4N DNA content shown by the NSMCE2 ligase-dead cell lines.  
 
This study has found that when decatenation is inhibited through ICRF-193 treatment, 
NSMCE2 ligase-dead cells were unable to activate or maintain the decatenation 
checkpoint since they do not arrest cell cycle progression. However, this was not found 
in the NSMCE2 knockout cell line. This finding gives support that the ligase-dead 
NMSCE2 may be ‘getting in the way’ of other cellular proteins which may be 
compensating for the loss of NSMCE2 activity, and indicates that NSMCE2 may be 
directly involved with activating and maintaining the decatenation checkpoint and 
perhaps in decatenation itself.  
 
Using immunofluorescence to visualise the cell size of each CRISPR-Cas9 NSMCE2 
mutant cell line revealed that there was an average increase in size of 1.2 times 
between the wild type and knockout cell lines. This is consistent with taking longer to 
move through the cell cycle as the cells continue to grow until they reach mitosis, 
particularly since there was no increase in DNA content shown through the FACS 
analysis. Moreover, the NSMCE2 ligase-dead cells increased in size by an average of 
1.4 times compared to wild type cells. This corresponds to continued cell growth due 
to the increased cell cycle length before, in many cases, failed cell division, since cells 
accumulate 8N DNA content. This supports the possibility that there is a segregation 
defect within the ligase-dead cells, possibly due to the inability to decatenate the DNA 
or activate the decatenation checkpoint. It is possible that there is also a chromosome 
segregation defect within the NSMCE2 knockout cells but it is at a much lower level as 
the increased DNA content was not detectable by the FACS analysis.  
 
As well as the possibility that the complex is involved in removing specific catenations, 
the inability to remove connnections between the DNA could be due to unresolved RS 
characteristics, such as cruciform structures which are formed upon the stalling or 
collapsing of replication forks, known to be resolved by the SMC5/6 complex (Gelot et 
al., 2015). The inability to remove RS characteristics, DNA mediated linkages, and so 
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separate sister chromatids, can cause cells with an incomplete S phase to move into 
early entry mitosis and so cause aneuploidy as they have problems with segregation 
(Mankouri et al., 2013). This could lead to the 8N DNA content noted in the NSMCE2 
ligase-dead cell line as the cells re-replicate the remaining abnormal DNA. This 
possibility is supported by a study which showed that some SMC5/6 mutants 
underwent chromosome nondysjunction and entered mitosis before finishing 
replication (Torres-Rosell et al., 2007).  The main questionmark above this theory, is 
that the prescence of the RS intermediates would cause the activation of the 
replication checkpoint which is not seen, although as discussed previously, this defect 
may not be sensed by the checkpoint.   
 
To investigate this further, immunoflourescence was used to study the quantity of 
micronuclei within each of the NSMCE2 cell lines. Micronuclei are extra-nuclear bodies 
of DNA known as the footprint of chromosome missegregation. They are often formed 
when cells enter mitosis without completing S phase due to RS intermediates 
remaining or other defects in chromosome segregation (Mankouri et al., 2013). There 
was a 3-fold increase in micronuclei content within the NSMCE2 ligase-dead cells 
further supporting their defect in chromosome segregation and possibly suggesting 
that RS characteristics, which leave DNA connections, may be causing these defects. 
However, interestingly, there was also a small, but significant, increase in micronuclei 
content in the NSMCE2 knockout cells compared to the wild type. This supports the 
conclusion that the knockout cells may also have a mild defect in chromosome 
segregation, possibly due to unresolved RS leaving DNA mediated connections 
between the sister chromatids. It is possible that whilst other proteins are mainly able 
to compensate for the loss of NSMCE2, the functional replacement is not perfect, 
leaving some mild phenotypes still present.  
 
This data indicates that the NSMCE2 subunit of the SMC5/6 complex may have a role 
in either decatenation directly, activation of the decatenation checkpoint or RS 
intermediate removal which can cause defects in chromosome segregation and cell 
division. I suggest that the most likely scenario is that problems faced during 
replication which cause the slowed progression in both the NSMCE2 ligase-dead and 
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knockout cell lines, leave RS intermediates, such as cruciform structures, within the 
ligase-dead cells as they cannot be repaired. These intermediates mean DNA 
connections between the sister chromatids remain, therefore causing cells to enter 
mitosis with an incomplete S phase, producing chromosome segregation problems. 
This is exacerbated as the NSMCE2 subunit of the SMC5/6 complex may also be 
normally involved in the removal of these and other connections between sister 
chromatids. It is possible that as the loss of NSMCE2 function is proposed to be mainly 
compensated for within the NSMCE2 knockout cells, the RS structures are not as 
prevalent, therefore little to no segregation defect is seen. It is also possible that 
instead of or as well as the accumulation of RS intermediates, the NSMCE2 ligase-dead 
cells are just slower at replication than the knockout cells, therefore leaving 
unreplicated regions of DNA which remain connected during mitosis. These 
connections would also inhibit or aid inhibition of appropriate chromosome 
segregation.  
 
Further work needs to be undertaken to investigate further and determine whether 
there is an increase in RS within the ligase-dead cell lines which could cause the 
segregation defects, such as by DNA combing. It would also be interesting to visualise 
the chromosome segregation through live cell microscopy with GFP expression to 
further investigate whether connections are present between the chromatids, their 
possible nature and how they affect the way in which the chromatids try and separate. 
To determine whether the NSMCE2 subunit also plays a role in removing protein 
cohesin linkages between sister chromatids, inhibition of separase which is required 
for cohesin removal, may also be carried out on each of the cell line before FACS 
analysis is carried out, to determine if there is a difference in the ability to then 
segregate their DNA after treatment (Hauf et al., 2001).  
 
4.5 The SUMOylation ability of NSMCE2 
 
The SUMOylation capabilities of NSMCE2 have always been important when studying 
the SMC5/6 complex as it often suggested that this may be the method by which the 
complex carries out many of its DNA repair and genome maintenance roles (Andrews 
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et al., 2005). Over the years of study, the NSMCE2 ligase capabilities have been 
associated with RS recovery, the removal of DNA cruciform structures and other 
replication intermediates, telomere elongation and homologous recombination as 
well as many other chromosome maintenance processes (Wu et al., 2012; Rai et al., 
2011; Chavez et al., 2010; Branzei et al., 2006; Potts and Yu, 2007). Despite the ever-
broadening knowledge of the importance of NSMCE2 SUMOylation in different cellular 
processes, few specific targets have been identified. 
 
Recently, a bioSUMO method has been developed to enable easy isolation of 
SUMOylated proteins from cell extracts (Pirone et al., 2016). It was thought that if this 
technique could be applied within wildtype MRC5 as well as the NSMCE2 mutant cell 
lines, it would enable the identification of NSMCE2 specific SUMOylation targets as 
these SUMOylated targets would not be present within the NSMCE2 knockout cell line 
compared to the wildtype cells. Therefore, the goal of this experimentation was to 
optimize the bioSUMO technique within wildtype cells using the known 
autoSUMOylation of NSMCE2 as a measurable readout (Andrews et al., 2005).  
 
Throughout this experimentation, we managed to efficiently express SUMO-1 that had 
undertaken in vivo biotinylation and was conjugated to cellular proteins within wild 
type MRC5 cells. We were then able to consistently recover this mixture of bio-SUMO-
conjugates using a stringent purification protocol. However, unfortunately, after many 
attempts of optimizing and repeating this experiment, we were unable to detect 
individual SUMO modified targets using western blotting. Many quality control 
methodology validating experiments were undertaken, testing the transfection 
efficiency as well as the binding and elution of SUMOylated proteins to the 
Streptavidin beads, which each confirmed the protocol was working in the manner it 
should. This provided further uncertainty as to why we could not achieve the results 
we expected. Due to time constraints, we were unable to continue developing this 
protocol further, however, it was possible to isolate a very small amount of RAN GAP1 
within one of the last experiments undertaken. As this is a largely SUMOylated protein 
within cells and there was only a very small amount of the SUMOylated protein 
detectable, this indicated several possibilities which could be used to optimize and 
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troubleshoot the protocol further (Matunis et al., 1996). These are; that the SUMO tag 
on the proteins was very labile and so was becoming removed, either from all cellular 
SUMOylated proteins or specifically from proteins we were attempting isolation of, 
during the binding, washing or elution process, that we were not using enough cellular 
material in order to detect the low levels of SUMOylated proteins found within cells 
or that the western blot technique was not sensitive enough and so mass 
spectrometry should be undertaken.  
 
Previous development of similar protocols within this lab has identified that in less 
than 8M urea SUMO/Ubiquitin tags can be labile and so could be becoming removed 
from tagged proteins during the binding stage. In light of this, this strategy would need 
to be repeated using higher concentrations of urea or guanidine during all stages to 
ensure the non-removal of the SUMO tags. If this still did not achieve the expected 
result, it would also be suggested to undertake mass spectrometry on the protein 





The purpose of this thesis was to validate and characterise CRISPR-Cas9 mutated 
NSMCE2 cell lines which had been created previously by this laboratory, enabling the 
ability to suggest possible roles for NSMCE2 and the SMC5/6 complex in chromosome 
maintenance and repair. It has been found that there was a mild proliferation defect 
within the NSMCE2 knockout cell line and a substantial proliferation defect within the 
NSMCE2 ligase-dead cell line both caused by slowed S phase progression. The NSMCE2 
ligase-dead cell lines also demonstrated >4N content by FACS analysis. The remainder 
of the project investigated the cause of these defects, determining that the replication 
checkpoint was not involved in the slowed S phase progression although the DNA 
damage checkpoint may be, particularly in the NSMCE2 ligase-dead cell lines. It has 
been identified that the most likely source of the proliferation defects was due to 
unresolved replication stress characteristics, unsensed by the replication checkpoint, 
which then cause further DNA damage and further slowed S phase progression. A 
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dominant negative mutation is expected to have caused the increased proliferation 
defect within the NSMCE2 ligase-dead mutant, as the ligase-dead NSMCE2 may disrupt 
other proteins compensating for its loss, such as proteins involved in replication stress 
characteristic resolution. This data also proposes that the NSMCE2 ligase-dead cell line 
has difficulty in segregating sister chromatids, causing the >4N DNA content. This may 
be due to the unresolved RS characteristics leaving DNA connections between the 
sister chromatids, or the NSMCE2 subunit of the SMC5/6 complex may also be directly 
involved in decatenating chromosomes before segregation or activating the 
decatenation checkpoint. Further work has been suggested to aid the specific 
identification of the chromosome maintenance and segregation actions undertaken 
by NSMCE2. A bioSUMO method for isolating specific NSMCE2 SUMOylation targets 
has been developed, with further technique recommendations made to ensure 
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